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The apicoplast is an essential organelle of P. falciparum. Currently, there are few 
molecular tools to identify and validate specific essential apicoplast proteins. We have 
therefore developed a molecular tool to probe the function of apicoplast-targeted proteins.  
 Nuclear-encoded proteins that are targeted to the apicoplast contain a transit peptide 
sequence that is essential for sorting proteins from the endoplasmic reticulum, into vesicles 
that fuse with the apicoplast outer membrane. Transit peptides have a unique requirement 
that they are unstructured during apicoplast import; furthermore, formation of structure in 
the transit peptide region blocks import. The goal of my thesis was to use this feature of 
transit peptides to design a conditional localization domain (CLD) tag that can control the 
localization of an apicoplast targeted protein. The CLD replaces the natural transit peptide 
of the target protein and traffics to the apicoplast under permissive conditions. An 
interacting ligand is added to the cell to bind the domain and cause the CLD to become 
secreted.  
We tested several proteins as potential CLDs and analyzed their ability to control 
trafficking of a fluorescent cargo protein using microscopy. Chapters 2 and 3 describe our 
efforts to design a suitable CLD from Dihydrofolate Reductase (DHFR) enzymes and the 
FK-506 Binding Protein (FKBP). The candidate domains we designed from DHFR were not 
suitable CLDs because they did not traffic to the apicoplast. Our initial design of a CLD 
from FKBP was also not a suitable CLD because it was too unstable to respond to the 
interacting ligand, although it was able to traffic to the apicoplast. We modified the original 
CLD designed from FKBP to generate three successful domains (CLD1, 2, and 3) that can 
be used to control the trafficking of apicoplast-targeted proteins. In Chapter 4 we analyzed 
the trafficking dynamics of CLD1, 2, and 3 in detail. Results show that CLD2 and CLD3 
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traffic to the apicoplast more efficiently than CLD1; we found that CLD1’s leaky apicoplast 
trafficking is caused by a higher protein stability compared to CLD2 or CLD3.  
To validate this system, we tested whether CLD1 or CLD2 could conditionally 
localize a parasite biotin ligase called Holocarboxylase Synthetase 1 (HCS1) without 
interfering with the function of the enzyme. HCS1 biotinylates the acetyl-CoA carboxylase, a 
protein that is only biotinylated in the apicoplast of liver stage parasites. In parasite lines that 
express CLD1-HCS1 or CLD2-HCS1, we were able to control protein biotinylation in the 
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Plasmodium falciparum Malaria 
 Malaria is a disease caused by 5 species of the Plasmodium parasite that infects 
humans. Plasmodium falciparum is the most prevalent Plasmodium species in Africa and 
according to the World Health Organization’s most recent report, 90 % of the 438,000 
deaths from malaria in 2015 occurred in the African region1.   Typical symptoms of Malaria 
include anemia, splenomegaly, and cyclical fevers but infection with P. falciparum can trigger 
more severe forms of disease such as cerebral malaria, which can lead to death in infants and 
children who are less than 5 years old. Given the severe impact of P. falciparum infection on 
young children, studies of the cell biology and immune response to this parasite are 
imperative to develop new treatments for the disease.  
P. falciparum has a complex life cycle that requires two hosts: female Anopheles 
mosquitos and humans. Humans are the intermediate host and are required for asexual 
replication and transmission of the parasite. The human stages of the parasite life cycle begin 
when a mosquito injects sporozoites into the skin while blood feeding. Sporozoites travel to 
the liver, and undergo a period of development in hepatocytes that lasts 5-6 days. 
Morphological changes occur in hepatocytes that allow the parasite to enter the blood 
stream, where it begins repeated cycles of asexual division in red blood cells2. Some parasites 
circulating in the blood split off from the asexual cycle and become gametocytes. 
Gametocytes are required for transmission of the parasite back to the mosquito during blood 
feeding.  
There are four stages of parasite development in the asexual blood cycle. Merozoites 
are the infectious stage that primarily invades reticulocytes (Figure 1-1 [1]). After invasion, 
the parasite enters the ring stage and begins catabolizing hemoglobin that is imported from 
the red blood cell cytosol (Figure 1-1 [2]) 3. Increases in parasite size and shape, as well as the 
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generation of Maurer’s clefts which are involved in export of parasite proteins to the red 
blood cell surface, mark the transition to the trophozoite stage (Figure 1-1 [3]) 4. In the final 
phase of development, schizonts prepare to release 16 or more newly formed merozoites 
(Figure 1-1 [4]). During the schizont stage the nucleus and other organelles required for cell 
survival and invasion are replicated and segregated into daughter merozoites 3 that are 
released from ruptured red blood cells.  
Most of the canonical and severe symptoms of malaria have been linked to parasite 
biology that occurs in the asexual cycle in red blood cells. For example, the release of 
merozoites at the end of each 48 hour cycle stimulates a pro-inflammatory immune response 
that causes cyclical fevers 5. This pro-inflammatory immune response also contributes to the 
development of severe anemia that is associated with Plasmodium infection. Pro-
inflammatory molecules negatively impact the maturation of erythroid cells, which leads to a 
reduction in erythropoesis6. Additionally, sequestration of late stages – trophozoites and 
schizonts – on brain endothelium is a major factor in the development of cerebral malaria 7. 
Sequestered parasites reduce perfusion around the brain tissue and cause hypoxia which 
exacerbates the symptoms of cerebral malaria8.  
Given that the symptoms associated with malaria are caused by the erythrocytic 
cycle, it is not surprising that several classes of antimalarial compounds target the 
erythrocytic cycle. For example, Quinolines are a class of anti-malarials that interfere with 
hemoglobin digestion, and Atovaquone collapses the mitochondrial membrane potential in 
blood stage parasites. Between the late 1950s and early 1980s however, widespread resistance 
to Chloroquine – a quinolone compound – arose, and resistance to several other classes of 
anti-malarials has been documented since then9. Due to Plasmodium’s historic ability to 
acquire drug resistance, it is important to continue to advance efforts to develop new anti-
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malarial compounds. One ideal target for development of novel anti-malarials is the 
apicoplast organelle.  
 
The Essential Apicoplast Organelle 
 An ancient eukaryotic ancestor of Plasmodium engulfed a algal cell which was 
reduced through evolution to the current apicoplast10. The apicoplast is a non-
photosynthetic plastid that is essential for parasite survival at all stages of development in the 
human host. Most of the protein coding genes previously encoded in the apicoplast have 
been transferred to the nucleus of the parasite11. As a result, nuclear encoded proteins that 
still function in the apicoplast must be post-translationally trafficked back to the organelle to 
perform their function.  
 Proteins that are active in the apicoplast perform essential functions at multiple 
stages of parasite development in the human host; and targeting apicoplast proteins for drug 
development could impact both the liver and blood stages of the parasite life cycle. For 
example, Plasmodium relies on the Type II Fatty Acid Synthesis (FASII) pathway in the 
apicoplast for production of lipids12,13. Studies of the FASII pathway in Plasmodium have 
revealed that FASII activity is required for progression from the liver stage to the blood 
stage of the parasite life cycle 14,15. Since mammalian cells rely on the Type I FAS pathway for 
lipid synthesis, targeting proteins required by the FASII pathway could inhibit growth of 
liver stage parasites and also prevent progression to the blood stage, without harming host 
cells.  
The apicoplast also houses the MEP (2-C-methyl-D-erythritol 4-phosphate) pathway 
for synthesis of isoprenoid precursors: isopentenyl pyrophosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP)16. Studies have shown that IPP and DMAPP are the only essential 
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products of the apicoplast in blood stage P. falciparum and treatment with drugs that inhibit 
the MEP pathway, kill the parasite17,18. Humans use a different pathway to synthesize 
isoprenoid precursors, and drugs that target the MEP pathway specifically, such as 
Fosmidomycin, have been successfully used to treat malaria in clinical trials19.  
Another group of proteins that has the potential to provide new drug targets against 
Plasmodium are proteins that are required for maintenance of the apicoplast organelle. 
Antibiotics inhibit apicoplast maintenance by blocking the activity of the ribosome in the 
apicoplast, which is responsible for translating a small number of proteins encoded in the 
apicoplast genome20,21. Studies from our lab have shown that the iron-sulfur (Fe-S) cluster 
synthesis pathway is also required for parasites to maintain the apicoplast and interfering 
with Fe-S cluster synthesis through expression of a dominant negative protein kills the 
parasite22. Other pathways could potentially be targeted inside the apicoplast that are 
essential for maintaining the apicoplast genome, organelle morphology, and protein import. 
Targeting proteins that are essential for apicoplast maintenance could be effective against 
both liver and blood stage parasites, since the apicoplast is essential at both stages of parasite 
development.    
Despite the importance of the apicoplast at multiple stages in the lifecycle, current 
knowledge of essential apicoplast biochemistry is largely based on predictions of the putative 
presence of nuclear-encoded proteins that contain the appropriate targeting motifs to allow 
them to be trafficked to the apicoplast 16. Increasing our knowledge of the essential pathways 
that are required for apicoplast maintenance and cell survival will improve our understanding 
of parasite biology and could provide insight into new drug targets for malaria treatment.  
 
Protein Trafficking to the Apicoplast  
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Soluble proteins are trafficked to the apicoplast via an N-terminal signal sequence 
and transit peptide motif 23–25. The signal sequence directs the protein to the endoplasmic 
reticulum (ER), where it is cleaved to reveal the transit peptide24. The transit peptide then 
further directs the protein to the apicoplast 25. A model of how proteins are trafficked to the 
apicoplast is shown in Figure 1-2 A.   
Several studies have helped to elucidate the characteristics of apicoplast transit 
peptides. Initially, researchers hypothesized that apicoplast transit peptides might have some 
features similar to the transit peptides of chloroplasts in plant cells. Apicoplast transit 
peptides however, do not appear to be similar to chloroplast transit peptides, and do not 
have a requirement for specific serine or threonine residues for trafficking24. Further studies 
showed that there is no specific amino acid sequence that is required for apicoplast 
trafficking. P. falciparum transit peptides must maintain a net positive charge near the N-
terminus, but the exact sequence of the positively charged residues is not important26. Our 
lab investigated whether there were any structural requirements for apicoplast transit 
peptides27. Nuclear magnetic resonance studies and mutational analysis of a confirmed 
apicoplast transit peptide sequence led to the discovery that transit peptides are unstructured 
during apicoplast import. These studies also showed that formation of structure in the transit 
peptide region blocks proteins from being imported to the apicoplast.  Finally, 
bioinformatics analysis of a group of putative apicoplast trafficked proteins revealed that 
transit peptides are typically between 24 and 150 amino acids in length28.   
The Acyl-Carrier Protein (ACP) was identified and verified early on as an apicoplast 
trafficked protein12,28. ACP is involved in fatty acid synthesis and is expressed in both liver 
and blood stage parasites29. Consequently, ACP is often used as a marker for the apicoplast 
and the trafficking motif from ACP has been appended to multiple fluorescent proteins to 
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illuminate the morphology of the apicoplast30. Figure 1-2 B, shows one such experiment 
where the targeting motif from ACP is appended to a green fluorescent protein and 
expressed in blood stage parasites.  The pattern of fluorescence in Figure 1-2 B shows the 
morphology of the apicoplast at the ring, trophozoite and schizont stages of development. 
At the ring stage, the apicoplast appears as a small dot that is usually located at the edge of 
the cell. In the trophozoite stage, the apicoplast branches out and can form almost any 
shape. In the schizont, the apicoplast divides into multiple daughter organelles that get 
segregated into each budding merozoite. 
Although there has been significant progress in defining the characteristics of transit 
peptides and the morphology of the apicoplast, there is still some debate about exactly how 
transit peptides direct trafficking to the apicoplast from the endoplasmic reticulum. Once the 
transit peptide is revealed in the endoplasmic reticulum, one hypothesis is that a currently 
unidentified receptor protein binds the transit peptide and sorts it into vesicles bound for the 
apicoplast outer membrane without trafficking through the Golgi31. This hypothesis is 
supported by experiments that showed that treating parasites with Brefelden A (Brefelden A 
collapses the Golgi complex) does not inhibit apicoplast trafficking31. More recent studies 
have conflicted with this model by showing that addition of an ER retrieval sequence to an 
apicoplast trafficked protein, reduces trafficking to the apicoplast32. This is significant 
because ER retrieval sequences are recognized in the Golgi and then trafficked back to the 
ER; In order for an ER retrieval sequence that is added on to an apicoplast targeted protein 
to be effective, the apicoplast targeted protein must traffic through the Golgi. This suggests 
that there may be a sorting branch point in the Golgi for apicoplast-targeted proteins.            
 
Molecular tools to investigate apicoplast-targeted proteins in P. falciparum 
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Currently there are only a few options for molecular tools to investigate apicoplast-
targeted proteins. Some of these options include genetic knockouts, which can only be 
applied to non-essential proteins, and conditional degradation domain tags 33,34. Conditional 
degradation domains are used to control the level of a specific protein in the cell. The 
protein of interest is tagged with the degradation domain and in the absence of an interacting 
ligand the domain destabilizes the protein and causes it to be degraded. When the ligand is 
added to cell culture media, the degradation domain stabilizes, which allows the protein to 
avoid degradation by the proteasome. Conditional degradation domains work well to control 
the level of cytosolic proteins, but are not as effective at controlling the level of proteins that 
traffic through the secretory pathway – this includes apicoplast-targeted proteins. 
Degradation domains may be less effective when tagging secretory proteins because they rely 
on the proteasome complex in the cytosol to reduce protein levels. Secretory proteins are co-
translationally imported into the ER and must be must be recognized and exported by the 
ER-associated degradation (ERAD) pathway before they can be degraded by the proteasome 
in the cytosol. The ERAD pathway may have differences in regulation or kinetics that 
prevents secretory proteins tagged with the degradation domain from being efficiently 
recognized or exported for degradation.  
RNA interference (RNAi) is a cellular pathway that is also commonly used to control 
protein levels in eukaryotic organisms 35.  RNAi is not applicable in P. falciparum because the 
parasite does not encode any of the essential RNAi pathway genes and lacks a functional 
RNAi pathway 36.  
Recently, a translational control molecular tool was designed for use in P. falciparum. 
This system requires the introduction of an aptamer sequence at the 3’ and 5’ ends of the 
target mRNA 37.  Under permissive conditions the aptamers interact with the Tet-repressor 
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(TetR) protein fused to a translational repressor (PfDOZI) to block translation of the target 
mRNA. Addition of anhydrotetracycline to the culture, prevents the TetR-PfDOZI repressor 
complex from interacting with the aptamer and allows the mRNA to be translated 37. This 
methodology may be difficult to implement with apicoplast-targeted proteins because 
introduction of an aptamer at the 5’ end of the mRNA, if translated with the leader peptide, 
could interfere with proper trafficking to the apicoplast. 
Given the small number of molecular tools available to control protein levels in 
Plasmodium, and the limitations of the current tools, the goal of my thesis was to develop a 
conditional localization system that would allow us to control the localization of apicoplast-
targeted proteins, and add to the field of molecular tools used in P. falciparum. The 
conditional localization system developed in this thesis is based on the use of a conditional 
localization domain (CLD) tag that we designed to be added as an N-terminal modification 
to a protein of interest and control its localization. Under permissive conditions the CLD 
traffics to the apicoplast and when an interacting ligand is added to the cell culture media, 
the CLD changes localization and is secreted from the cell. To design the CLD we tested 
two modified proteins as potential domains based on their previous use as degradation 
domains in P. falciparum. Chapter 2 described our initial attempts to design a CLD from the 
Dihydrofolate Reductase (DHFR) protein and Chapter 3 describes our final design of the 
CLD from the FK-506 Binding Protein (FKBP).  
 
Dihydrofolate Reductase Protein and Ligands 
 DHFR is an essential enzyme in the folate metabolism pathway of both prokaryotic 
and eukaryotic cells. DHFR binds dihydrofolate (DHF) and the cofactor NADPH, and 
generates tetrahydrofolate (THF) and NADP+. THF is an essential cofactor for synthesis of 
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purine molecules, some amino acids, and most importantly, thymidine nucleotides38. DHFR 
activity supports the growth of rapidly dividing cells in cancer by maintaining high levels of 
THF for thymidine synthesis. Specific inhibitors of DHFR activity, such as methotrexate 
(MTX) are used as chemotherapeutic agents39 .  
The crystal structure of DHFR in complex with MTX and NADPH is shown in 
Figure 1-3 A. DHFR has a complex structure made up of four alpha helices and an 8-strand 
beta sheet that fold to create two binding domains. The discontinuous loop domain (violet 
colored structure in Figure 1-3 A) binds DHF or a folate analog (MTX), and the adenosine-
binding domain (cyan colored structure in Figure 1-3 A) binds NADPH40. The structure in 
Figure 1-3 A shows that the DHFR interaction domains bring folate and NADPH into close 
association when bound to DHFR, and studies have shown that NADPH facilitates 
cooperative binding between DHFR and another folate analog, trimethoprim (TMP)41. TMP 
(structure shown in Figure 1-3 B) has enhanced specificity for bacterial DHFR enzymes and 
is used as an antibiotic38. In our studies we expressed DHFR in parasites as a candidate CLD 
and we used TMP as the interacting ligand in these experiments.  
 
FK-506 Binding Protein and Ligands 
   FKBP is a prolyl isomerase that is normally active in the cytosol as a protein folding 
chaperone42. FKBP was identified as the target of two immunosuppressive agents isolated 
from bacteria: FK-506 and Rapamycin. Both of these compounds form complexes with 
FKBP that interfere with the cellular immune response by blocking signal transduction 
pathways that are required for T-cell activation42. FKBP has a much simpler structure than 
DHFR that consists of a 5-strand anti-parallel beta sheet that wraps in a right handed twist 
around a short alpha helix (Figure 1-4 A)43. The side chains of the beta sheet form a 
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hydrophobic pocket where the FK-506 ligand binds.  
The FKBP/FK-506 protein and ligand combination has been re-purposed for use as 
a molecular tool in multiple eukaryotic cell systems44. FKBP and FK-506 have both been 
modified in many of these molecular tools to create a more high affinity protein-ligand 
interaction45. The structure of FK-506 is shown in Figure 1-4 B with the conserved core 
region highlighted in red. This conserved core region binds in the hydrophobic pocket of 
FKBP and is maintained in most FK-506 derivatives. Studies of the carbonyl oxygen 
highlighted with an arrow in Figure 1-4 B have found that this region of the compound 
interacts with the amino acid side chains depicted in Figure 1-4 A (Tyr26, Phe36, and 
Phe99)45. Mutating the phenylalanine at position 36 to valine creates a hole in the 
hydrophobic pocket of FKBP that is compensated by the replacing the highlighted carbonyl 
oxygen in FK-506 with a trimethoxyphenyl group to create the Shield1 ligand (Shield1 
structure is shown in the bottom panel of Figure 4-1 B). Shield1 is an FK-506 derivative that 
has a binding affinity (Kd) of 0.094 nM for the FKBPF36V mutant, compared to 67 nM for the 
wild type protein45. Shield1 is commonly used as the ligand for FKBPF36V when FKBP is used 
as a molecular tool in P. falciparum and in other eukaryotic cells.          
 
Thesis Rationale 
This thesis will describe the design, evaluation, and validation, of a conditional 
localization domain tag that can be used to control the localization of specific apicoplast 
targeted proteins. Previous studies in our laboratory on the targeting motifs required for 
apicoplast trafficking were instrumental in the conceptualization of the apicoplast 
conditional localization domain27.These studies showed that P. falciparum transit peptides 
must be unstructured to traffic to the apicoplast, and that the formation of structure in the 
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transit peptide region blocks apicoplast import 27. My thesis builds on this understanding of 
the structural requirements of transit peptides to engineer a conditional localization domain 
that can be added as an N-terminal tag to a protein of interest and replace the transit peptide 
motif. In the absence of an effector ligand the CLD mimics a natural transit peptide region, 
and is unstructured to allow the protein to traffic to the apicoplast. When the effector ligand, 
binds to the CLD, it stabilizes the structure of the protein and causes the CLD to be 
secreted from the cell. A model of the conditional localization system designed in this thesis 
is shown in Figure 1-5.  
To engineer a CLD, we designed and tested multiple proteins as candidate CLDs. 
We reasoned that a destabilized protein would be an ideal starting point for the design of the 
CLD. Our overall hypothesis was that the destabilized version of the CLD could mimic an 
unstructured transit peptide region and traffic to the apicoplast, and addition of a binding 
ligand to stabilize the structure of the CLD could cause the protein to be secreted. Two 
destabilized proteins have been expressed in P. falciparum as conditional degradation 
domains: Dihydrofolate Reductase and FK-506 Binding Protein 33,34.  We modified both of 
these proteins to more closely mimic a P. falciparum transit peptide and expressed them in P. 
falciparum to test if they were suitable candidates to be the conditional localization domain 
tag. Studies of the DHFR protein (Chapter 2) showed that DHFR could not be used as a 
CLD because it does not traffic to the apicoplast. We were however, able to design three 
successful CLDs by modifying the FKBP sequence (Chapter 3). We characterized the 
trafficking dynamics of each CLD designed from the FKBP protein in Chapter 4. And 
finally, in Chapter 5 we validated two of the CLDs by tagging the active parasite biotin ligase, 
Holocarboxylase Synthetase 1 (HCS1; PlasmoDB PF3D7_1026900). We were able to 
control the localization and activity of this enzyme in the apicoplast using the conditional 
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localization domain. The apicoplast conditional localization system designed in this thesis 
can be added to the list of molecular tools for investigating the molecular biology of P. 
falciparum and will be useful in future studies of the function of specific apicoplast targeted 
proteins that could provide novel drug targets for Malaria.   
  
14 
Figure 1-1 The erythrocytic cycle of P. falciparum 
[1] Merozoites actively invade red blood cells (RBC) to begin the asexual division cycle.  
[2] After invasion the ring stage parasite begins to feed on the red blood cell cytosol.  
[3] The trophozoite expands in size and sets up export machinery for parasite proteins in the 
RBC cytosol.  
[4] Mature schizonts have replicated the cellular DNA and organelles required for invasion 
and separated them into daughter merozoites. Merozoites are released from the ruptured 







Figure 1-2 Protein trafficking in Plasmodium 
A) Nuclear encoded proteins that are trafficked to the apicoplast contain an N-terminal 
signal sequence and transit peptide. The signal sequence directs the protein to be co-
translationally imported into the ER, where it is cleaved to reveal the transit peptide. The 
transit peptide then further directs the protein to the apicoplast.  
Ap = Apicoplast, PV = Parasitophorous Vacuole, ER = Endoplasmic Reticulum,  
Nu = Nucleus, Gg = Golgi, Signal Seq. = Signal Sequence, Transit Pep. = Transit Peptide 
 
B) Live fluorescence images of a transgenic parasite line that expresses the Super Folder 
Green fluorescent protein with an N-terminal trafficking motif from a verified apicoplast 
resident protein (the Acyl-Carrier Protein). This parasite line allows us to visualize the 
apicoplast morphology at each stage of parasite development. Images are 10 microns wide 
by 10 microns long. 
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Figure 1-3 Structure of Dihydrofolate Reductase and Trimethoprim 
A) Crystal structure of the E. coli DHFR protein in a complex with methotrexate (MTX) and 
the co-factor NADPH46.  
B) Chemical structure of Trimethoprim (PubChem CID: 5578)
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Figure 1-4 Structure of FK-506 Binding Protein, FK-506, and Shield1 
A) Crystal structure of the human FKBP protein. Amino acid side chains that directly 
interact with the modified carbonyl oxygen highlighted in the FK-506 structure are shown. 
The phenylalanine at position 36 was mutated to valine to create a cavity in the hydrophobic 
pocket. 
B) Top panel shows the chemical structure of FK-506 that was first isolated from Streptomyces 
tsukubaensis (CID: 445643). The region colored in red is a conserved core region that binds in 
the hydrophobic pocket of FKBP. The arrow points to a carbonyl oxygen that was modified 
to create Shield1. Bottom panel shows the chemical structure of Shield1 (CID: 44455162). 
Shield1 is an FK-506 derivative that has a higher binding affinity for FKBPF36V than the wild 
type FKBP.    
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Figure 1-5 Model of the apicoplast conditional localization system 
The CLD is added as an N-terminal tag to a protein of interest and replaces the natural 
protein trafficking motif. In the absence of an interacting ligand (− Ligand, left side) the 
CLD is unstructured and mimics a natural transit peptide, which allows the cargo protein to 
traffic to the apicoplast. When an interacting ligand is added to the culture media (+ Ligand, 
right side), the structure of the CLD is stabilized and this causes the cargo protein to be 
secreted from the cell. Proteins that are secreted accumulate in the parasitophorous vacuole 
space that separates the red blood cell cytosol from the parasite.   
Ap = Apicoplast, PV = Parasitophorous Vacuole, ER = Endoplasmic Reticulum,  
Nu = Nucleus, SS = Signal Sequence, CLD = Conditional Localization Domain,  
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This chapter will describe our attempts to engineer a Conditional Localization 
Domain (CLD) from the Dihydrofolate Reductase (DHFR) proteins of Escherichia coli 
(CLD:EcDHFR) and Mus Musculus (CLD:MmDHFR). To determine if a candidate CLD is 
suitable for our conditional localization system we expressed each candidate CLD in 
parasites with a C-terminal fluorescent cargo protein. We then analyzed the localization of 
the protein in the presence and absence of an interacting ligand. The candidate CLD must 
traffic to the apicoplast under permissive conditions and change localization when the ligand 
is added to cell culture media in order to be considered a suitable domain for further studies. 
CLD:EcDHFR failed to traffic to the apicoplast or change localization when the ligand was 
added to cell culture media.  While CLD:MmDHFR also failed to traffic to the apicoplast 
under permissive conditions, it was able to change localization and become secreted upon 
the addition of an interacting ligand. Both candidate CLDs appear to accumulate in the 
secretory space under permissive conditions.  
We hypothesized that the failure of CLD:EcDHFR and CLD:MmDHFR to traffic to 
the apicoplast could be because the DHFR protein is toxic in the apicoplast organelle. We 
investigated this hypothesis by attempting to generate a transgenic parasite line that 
constitutively over-expresses DHFR in the apicoplast. Multiple transfections in P. falciparum 
failed to over-express EcDHFR or MmDHFR in the apicoplast. This suggested to us that the 
enzymatic activity of DHFR might be harmful to the apicoplast.  
Ultimately, neither of the candidate CLDs tested in this chapter were successful 
because they did not traffic to the apicoplast and were eliminated as candidates to be the 
final domain. Our analysis of these domains however, informed and helped refine our 





To design a CLD that is effective for our apicoplast conditional localization system 
we tested multiple proteins as candidate conditional localization domains. Our goal in the 
design of each candidate CLD was to mimic an apicoplast transit peptide under permissive 
conditions to allow the CLD to traffic to the apicoplast. Our second major design goal was 
to give the CLD structural properties that could be altered experimentally to change the 
localization of the CLD. Once we designed a candidate CLD we generated transgenic 
parasite lines that express the domain fused to a fluorescent cargo protein, so that we could 
evaluate its localization using live fluorescence microscopy. When analyzing protein 
localization we expect to see the typical branched apicoplast morphology (Figure 2-1 A) to 
indicate that the CLD is trafficking to the apicoplast. After addition of an interacting ligand 
to alter the structure of the CLD we looked for a change in trafficking pattern (Figure 2-1 B) 
to indicate that the CLD is secreted from the cell.  
 We began our studies with two candidate CLDs designed from Dihydrofolate 
Reductase (DHFR). DHFR is a highly studied enzyme that is involved in folate metabolism 
and is required for synthesis of thymidine nucleotides1,2. DHFR proteins from multiple 
species have been successfully expressed in P. falciparum as molecular tools. The human 
DHFR gene is most often expressed in P. falciparum as a selection cassette to generate 
transgenic parasite lines3,4. Human DHFR can be used to select transgenic parasites because 
anti-folate compounds have different specificities for vertebrate and bacterial DHFR 
proteins5; The DHFR protein from P. falciparum is targeted by some anti-folates, such as 
WR99210, that are active against bacterial DHFR proteins but not the human DHFR 3. In 
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general, to create a transgenic parasite line through homologous recombination, parasites are 
transfected with a plasmid that contains the human DHFR gene, in addition to the 
homologous region of the gene that researchers are trying to disrupt. To promote integration 
of the transfection plasmid, parasites are treated with WR99210, which forces the parasites 
to integrate or maintain the transfection plasmid in order to express the human DHFR 
protein that is not affected by WR99210. Parasites that integrate the transfection plasmid are 
selected over time by cycling on and off of WR99210.  
A conditionally destabilized mutant of E. coli DHFR (EcDHFR) is commonly 
expressed in P. falciparum as a conditional degradation domain tag 6–8. This degradation 
domain was used to show that the proteasome lid subunit PfRpn6, is essential for ubiquitin 
related protein degradation and parasite survival in the blood stage7. PfATG7 is an autophagy 
related gene that was also tagged with the degradation domain and was found to be essential 
for normal parasite growth in the blood stage8. The first candidate CLD we tested was 
designed from the destabilized EcDHFR protein. Destabilized EcDHFR was modified to 
mimic an apicoplast transit peptide and expressed in P. falciparum (CLD:EcDHFR). We 
hypothesized that the destabilized EcDHFR would resemble an unstructured transit peptide 
and allow the CLD to traffic to the apicoplast in the absence of a ligand. We further 
hypothesized that addition of the binding ligand Trimethoprim (TMP) to stabilize the 
structure of CLD:EcDHFR would block import to the apicoplast and cause the CLD to be 
secreted from the cell.   
 The DHFR protein form M. musculus (MmDHFR) has also been used as a molecular 
tool in P. falciparum. In a study of how proteins are exported to the red blood cell cytosol, 
MmDHFR was used to show that proteins must be unfolded to cross the parasitophorous 
vacuole membrane9. In this study, researchers expressed a green fluorescent protein fused to 
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MmDHFR in the secretory pathway of parasites. In the absence of the binding ligand (TMP), 
MmDHFR could be unfolded to allow GFP to cross the vacuolar membrane through the 
PTEX translocon. When TMP was added to cell culture media, MmDHFR stabilized and 
prevented GFP from crossing the vacuolar membrane. Although MmDHFR has not been 
used as a conditional destabilization domain, we hypothesized that the change in stability of 
the wild type protein in the presence of TMP might be sufficient to change the localization 
of the CLD. We therefore tested MmDHFR as our second candidate CLD 
(CLD:MmDHFR).  
 To get an idea of how well each CLD sequence meets the requirements of a P. 
falciparum transit peptide, we input the amino acid sequences into the Predictor of Apicoplast 
Targeted Sequences (PATS) computer program10. The PATS algorithm analyzes amino acid 
sequences to determine if an apicoplast trafficking motif is present and gives an output score 
between 0 and 1. A score of 0 indicates that the input sequence does not contain an 
apicoplast trafficking motif and is not likely to traffic to the apicoplast. A score of 1 indicates 
that the sequence does appear to contain an apicoplast trafficking motif and is likely to 
traffic to the apicoplast. Although the PATS program is a useful tool to evaluate whether the 
CLD sequences we design are similar in terms of amino acid sequence features to a natural 
apicoplast transit peptide, there are some limitations of the algorithm. The PATS algorithm 
was developed before the full P. falciparum genome sequence was completed and only uses 
information from chromosomes 1 and 2 to make its predictions. The algorithm was trained 
from 84 likely apicoplast trafficked and 102 non-apicoplast trafficked sequences10. 
Information from the complete sequence of the P. falciparum nuclear genome has revealed 
that there are over 500 nuclear encoded proteins that are likely trafficked to the apicoplast11. 
Additional training of the PATS algorithm, based on the full genome sequence of P. 
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falciparum could improve the accuracy of its predictions. The PATS algorithm also does not 
consider structural features of the transit peptide region, which our lab has shown in 
previously described studies (Chapter 1), are an important characteristic of transit peptides. 
Despite these limitations of the PATS program, we still found it to be a useful tool to guide 
the design of each candidate CLD.   
We analyzed protein trafficking in parasite lines that express either CLD:EcDHFR or 
CLD:MmDHFR fused to a fluorescent cargo protein.  Both of these CLDs were tested with 
the interacting ligand TMP.  Neither CLD trafficked to the apicoplast under permissive 
conditions (- TMP) and CLD:EcDHFR did not change localization when TMP was added to 
cell culture media. CLD:MmDHFR however, did change localization when TMP was added 
and was secreted from the cell.    
Since DHFR is not usually expressed in the apicoplast of wild type parasites, we 
investigated whether over-expression of DHFR in the apicoplast could be toxic to parasites. 
The apicoplast houses essential biochemical pathways that could be perturbed by the over 
expression of an enzyme that is not normally present in the organelle. To test if DHFR can 
be over-expressed in the apicoplast we attempted to generate transgenic parasite lines that 
constitutively traffic DHFR to the apicoplast using a verified apicoplast trafficking motif 
from ACP. Multiple transfections using high and low strength promoters failed to express 
DHFR in the apicoplast compartment. This suggested to us that there could be some 
toxicity associated with over-expressing DHFR in the apicoplast. Since both of the candidate 
CLDs designed from DHFR proteins also failed to traffic to the apicoplast, we did not do 





Design and Expression of CLD:EcDHFR 
 To design our first candidate conditional localization domain we mutated the 
destabilized EcDHFR to mimic a P. falciparum transit peptide. As discussed in Chapter 1 
transit peptides must maintain a net positive charge near the N-terminus and they must be 
unstructured to traffic to the apicoplast. To meet the positive charge requirement of transit 
peptides, we mutated a negatively charged aspartic acid at position 11 and a glutamic acid at 
position 17 to positively charged lysine (EcDHFRD11K, E17K). This increased the overall charge 
near the N-terminus of the CLD +4 (Figure 2-2 A). The destabilized EcDHFR that has been 
used as a degradation domain in other studies has an asparagine to threonine mutation at 
residue 18 and an alanine to valine mutation at position 19 (EcDHFRN18T, A19V) 
7. These 
mutations were also made in the CLD:EcDHFR sequence to conditionally destabilize the 
CLD. There are no specific sequence motifs required for recognition of apicoplast trafficked 
proteins and so no further changes to the EcDHFR sequence were applied to generate the 
CLD. CLD:EcDHFR received a PATS score of 0.89, which is comparable to PATS scores 
computed from known apicoplast trafficked sequences. This suggested to us that the 
sequence of CLD:EcDHFR closely mimics an apicoplast trafficking peptide and could 
potentially traffic the test cargo protein to the apicoplast.  
We expressed CLD:EcDHFR in parasites with an N-terminal signal sequence to 
allow the protein to be co-translationally imported into the endoplasmic reticulum (Figure 2-
2 A). We also added a C-terminal Green Fluorescent Protein (GFP) tag to the CLD so that 
we could track its localization.  We investigated the localization of GFP in the presence and 
absence of the interacting ligand (TMP) using live fluorescence imaging. In Figure 2-2 B, the 
top panel shows that GFP does not take on the branched localization pattern that is 
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indicative of apicoplast trafficking in the absence of the interacting ligand TMP. Instead, 
GFP appears to accumulate in the secretory space, which suggests that CLD:EcDHFR is not 
recognized as a transit peptide by the parasite. When TMP is added to the culture media 
(Figure 2-2 B, bottom panel), there is no change in localization of GFP.  
We also analyzed fixed cells in immunofluorescence images to confirm that 
CLD:EcDHFR does not traffic to the apicoplast. Co-localization analysis of cells stained 
with anti-ACP (ACP is an apicoplast marker discussed in Chapter 1) and anti-GFP 
antibodies revealed no significant co-localization between these two proteins (Figure 2-2 C), 
confirming that CLD:EcDHFR does not traffic to the apicoplast.  
 
Design and Expression of CLD:MmDHFR 
 The second candidate CLD we tested was the wild type sequence of the MmDHFR 
protein. The wild type MmDHFR sequence does not contain any negatively charged residues 
near the N-terminus, and so we did not make mutations to alter the charge (Figure 2-3 A). 
Although MmDHFR has not been engineered to create a conditionally destabilized version 
of the protein, it has been used as a molecular tool in P. falciparum (see description in 
introduction), and we tested this protein as a candidate CLD without any destabilizing 
mutations. We also put the CLD:MmDHFR sequence into the PATS program to estimate its 
likelihood of trafficking to the apicoplast. CLD:MmDHFR got a score of 0.97 from the 
PATS program, which suggests that the wild type MmDHFR sequence has basic sequence 
similarities with other apicoplast transit peptide motifs.  
 We expressed CLD:MmDHFR in parasites with an N-terminal signal sequence and 
the Super Folder Green (SFG) fluorescent protein at the C-terminus. SFG is an enhanced 
green fluorescent protein that has been optimized for expression in the secretory 
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pathway12,13. In the absence of TMP, CLD:MmDHFR appears to accumulate in the secretory 
space (Figure 2-3 B, top panel), similar to the trafficking pattern of CLD:EcDHFR. When 
TMP is added to cell culture media however, CLD:MmDHFR does change localization. 
CLD:MmDHFR is secreted from the cell and accumulates in the parasitophorous vacuole 
space (Figure 2-3 B, bottom panel). We confirmed that CLD:MmDHFR does not traffic to 
the apicoplast in the absence of TMP, by staining fixed cells with anti-ACP and anti-GFP 
antibodies in immunofluorescence assays. No significant co-localization was observed 
between SFG and the apicoplast marker ACP (Figure 2-3 C), indicating that CLD:MmDHFR 
does not traffic to the apicoplast.  
 
Expression of DHFR in the Apicoplast     
In our next experiment, we investigated whether over-expression of DHFR in the 
apicoplast is toxic to parasites. Parasites were transfected with plasmids that contain the full-
length apicoplast trafficking motif (signal sequence and transit peptide) from the Acyl-
Carrier Protein (ACP) fused to the wild type sequence of EcDHFR or MmDHFR. Both of 
the DHFR proteins were exogenously expressed from a high (calmodulin) or low (ribosomal 
L2 protein) strength promoter. Our lab’s experience with protein over-expression in the 
apicoplast has been that some enzymes are not tolerated in the apicoplast when expressed 
from a high strength promoter like the P. falciparum calmodulin promoter. In these cases, 
switching expression of the transgene to a lower strength promoter like the ribosomal L2 
promoter can rescue the viability of the parasites. However, this was not the case with 
DHFR. Out of four successful transfections where drug resistant parasites were selected, 
none of the parasites expressed EcDHFR or MmDHFR in the apicoplast from a high or low 
strength promoter (Table 2-1). In each of these experiments, parasites have presumably 
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found a way to turn off expression of the transgene (Apicoplast trafficked DHFR), while 
maintaining expression of the selection cassette. This suggests that over-expression of 
DHFR in the apicoplast, even at low levels, is toxic to the parasite, possibly because of the 
enzymatic activity of the protein. 
 
CONCLUSIONS AND DISCUSSION 
 
 Analysis of protein trafficking by CLD:EcDHFR and CLD:MmDHFR as potential 
CLDs revealed that neither of these domains were able to traffic a test protein (GFP or 
SFG) to the apicoplast (Figure 2-2 and 2-3 respectively). CLD:MmDHFR was moderately 
more successful as a CLD because it could change localization of the test protein when TMP 
was added to cell culture media. This result supported our hypothesis that stabilizing the 
structure of the CLD could change the localization of a protein. But, since neither of the 
candidate CLDs trafficked to the apicoplast, they could not be used as a conditional 
localization domain.  
Both CLDs appear to get hung up in the secretory pathway without being recognized 
as an apicoplast transit peptide. This trafficking pattern could be because DHFR has the 
ability to bind multiple ligands – dihydrofolate and/or NADPH – independently in the 
endoplasmic reticulum1. If DHFR binds NADPH in the endoplasmic reticulum, this could 
stabilize the protein and prevent the CLD from trafficking to the apicoplast. 
 We also investigated whether DHFR has some toxic effect that would lead the 
parasite to avoid expressing this enzyme in the apicoplast. We attempted to generate parasite 
lines that over-express DHFR in the apicoplast to show that the enzyme activity is not toxic. 
None of the transfected parasites were able to express DHFR in the apicoplast from a high 
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or low strength promoter (Table 2-1). This suggests that there may be some toxicity 
associated with expressing the DHFR enzyme in the apicoplast. One theory to explain why 
DHFR is toxic is again linked to DHFR’s ability to bind the cofactor NADPH. DHFR could 
bind NADPH in the apicoplast and reduce the pool of NADPH that is available for use by 
the MEP pathway. The MEP pathway is essential because it synthesizes isoprenoid 
precursors that are required for development of blood stage parasites14. Over expression of 
DHFR in the apicoplast may sufficiently reduce the pool of available NADPH so that the 
apicoplast is no longer able to synthesize isoprenoids and the cell dies.  
At this point in the progression of my thesis, we decided not to further investigate 
CLD:EcDHFR or CLD:MmDHFR.  Our overall goal was to design a CLD that could be 
used to control trafficking of apicoplast targeted proteins and it was clear from these studies 
that DHFR could not easily be converted into a CLD because it does not readily traffic to 
the apicoplast. Our analysis of these failed CLDs was useful however, to inform our design 
specifications for the next candidate CLD.  
One feature of DHFR proteins in general that may not have worked in our favor for 
these studies is that DHFR can bind multiple ligands (most significantly, NADPH) that 
could be present in the ER and apicoplast compartments. NADPH binding would affect 
DHFR stability, but it would also increase the affinity of other ligands like DHF or TMP 
since these ligands bind in a cooperative manner. As previously discussed, this activity of 
DHFR could interfere with trafficking of DHFR to the apicoplast, or disrupt essential 
pathways that function in the apicoplast. When considering the design of our next candidate 
CLD we chose a protein that does not have as many potential binding partners in the cell.  
A second feature of both of the CLDs tested in this chapter that may have 
contributed to their inability to traffic to the apicoplast is that they are both quite stable. 
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Although degradation domain mutations were introduced into the EcDHFR sequence, 
preliminary studies in which we purified destabilized EcDHFR found that the melting 
temperature of the CLD was not significantly different from that of the wild type protein. 
The level of instability required for apicoplast trafficking has not been precisely measured, 
but we reasoned that starting from a more severely destabilized protein for our next 
candidate CLD could increase its likelihood of trafficking to the apicoplast. 
A third feature of DHFR proteins that may have contributed to their inability to 
traffic to the apicoplast is the amino-terminal structure of DHFR. The amino-terminus of 
DHFR is buried in the binding domain of the protein and may not be available for 
recognition as a transit peptide even if the protein is slightly destabilized (Figure 2-4 A).  
A final feature of both DHFR proteins tested is that they are longer than the typical 
size of a natural P. falciparum transit peptide. The maximum length of most P. falciparum 
transit peptides is about 150 amino acids long while EcDHFR is 159 amino acids and 
MmDHFR is 187 amino acids long. Transit peptide length may be more important for 
recognition than we anticipated with these candidate CLDs, and in our next study we chose 
a protein that is significantly smaller than DHFR. 
 Our next candidate CLD was designed to take most of the previously discussed 
pitfalls of DHFR into account. The human FK-506 Binding Protein (FKBP) is within the 
normal size range of a transit peptide, it does not bind a co-factor to perform its normal 
function in the cell and it has a degradation domain mutation that is significantly more 
severe than the destabilized EcDHFR protein. FKBP also has a less complex structure near 
the amino-terminus which is likely to be more available for recognition as a transit peptide 





Generation of plasmid constructs 
 The wild type E. coli DHFR gene was harmonized for expression in P. falciparum 
(Table 2-2) and synthesized by GeneArt (Life Technologies). Adaptamers were then used to 
insert the signal sequence from the ACP gene (see Apico20.AvrNdeF and 
Apico20Avr.NdeR sequences in Table 2-3) at the N-terminus of EcDHFR. To generate N-
terminal lysine mutations and degradation domain mutations in the EcDHFR sequence, 
Akk.MutUF and Akk.mutUR primers from Table 2-3 were used with Pfu DNA polymerase 
for mutagenesis in the GeneArt cloning vector. The entire CLD:EcDHFR sequence was 
then cut out of the GeneArt cloning vector using AvrII and BsiWI and ligated into a 
modified pLN 15 vector for parasite transfection that contained the lower strength ribosomal 
L2 protein promoter 16 instead of the calmodulin promoter.  
 The signal sequence and transit peptide from the ACP gene were PCR amplified 
from the pMALcHT-ACP plasmid 17 using the Api55.AvrII.F and Api55.NdeI.R primers 
listed in Table 2-3. The PCR products were then digested with AvrII and NdeI and ligated 
into the GeneArt cloning vector that contained the wild type EcDHFR sequence using quick 
ligase. The entire Signal (ACP)-Transit (ACP)-EcDHFR sequence was then cut out of the 
GeneArt cloning vector using AvrII and BsiWI and ligated into a pLN vector with either the 
calmodulin or ribosomal L2 promoter.  
 The wild type MmDHFR sequence was amplified from the pMALcHT-mDHFR 
plasmid using the mDHFR.NdeI.F and mDHFR.BglII.R primers in Table 2-3. The PCR 
amplicon was digested with NdeI and BglII and ligated into the GeneArt cloning vector 
described above and replaced the EcDHFR sequence. The signal sequence or signal 
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sequence and transit peptide together were inserted into the cloning vector with MmDHFR 
using the same procedure described above. The entire targeting motif and MmDHFR 
sequence was then digested out of the GeneArt cloning vector using AvrII and BsiWI. The 
fragment was finally ligated into the pLN vector with calmodulin or ribosomal L2 promoters 
and the super folder green sequence.  All plasmids were sequenced to confirm correct 
insertions after ligation.  
 
Parasite transfection and culture 
Parasites were cultured at 2 % hematocrit in RPMI 1640 medium containing 25 mM 
HEPES, 0.375% sodium bicarbonate, 12.5 μg/ml hypoxanthine, 5 g/L Albumax II and 
25μg/ml gentamicin. Transfections were done using the Bxb1 mycobacteriophage integrase 
system in the Dd2 strain of parasites that contain an attB site for recombination15. 
Uninfected red blood cells were preloaded with transfection plasmids and electroporated 
using the protocol from Spalding et al 2010 18. Electroporated red blood cells were then 
mixed with parasite culture and after two days of growth transgenic parasites were selected 
with 2.5 μg/ml Blasticidin. 
 
Live cell imaging 
 Parasite cultures were stained with DAPI and MitoTracker Red CMX Ros 
(Invitrogen). 100 μl of parasite culture was incubated for 30 minutes in 1 μg/ml DAPI and 
30 nM MitoTracker Red CMX Ros at 37 °C. Samples were then washed three times in 
culture media and pipetted onto microscope slides. A coverslip was placed over the slide and 
sealed with wax (2 parts paraffin, 1 part Vaseline). Samples were then taken immediately to 




Microscope slides were set up for immunofluorescence assays by drawing wells on 
the slide with a Super Pap Pen Liquid Blocker (Ted Pella, inc.). A .01 % poly-L-Lysine 
solution (Sigma-Aldrich) in water was added to each well and allowed to dry for at least 30 
minutes. 300 μl of parasite culture was then pelleted and resuspended in an equal volume of 
fixative (4 % paraformaldehyde and .0075 % glutaraldehyde in PBS). Cells were added to 
each well on the slide and then incubated for 30 minutes at room temperature. After 
incubation, fixed cells were permeabilized by incubation in 1 % Triton X-100 for ten 
minutes. The samples were then reduced by incubation in 100 μg/ml NaBH4 in water for 10 
minutes. Next the cells were incubated in blocking solution (3 % BSA in PBS) for two 
hours. Before applying primary antibodies cells were washed in PBS and then incubated with 
appropriate antibodies overnight at 4 °C [rabbit polyclonal αACP 1:500, raised against the P. 
falciparum antigen; Living Color mouse monoclonal αGFP 1:100 (CloneTech)]. The next day, 
cells were washed three times in PBS and then once in 3 % BSA. Appropriate secondary 
antibodies  [goat αrabbit AlexaFluor 594 1:1000 (Life Technologies); goat αmouse 
AlexaFluor 488 1:1000 (Invitrogen)] were added to cells and incubated for 2 hours in the 
dark at room temperature. Finally cells were washed in PBS three times and sealed with 
ProLong Gold antifade reagent with DAPI (Life Technologies) under a coverslip sealed with 
nail polish. Slides were allowed to sit overnight at room temperature before imaging analysis 





Figure 2-1 Comparison of apicoplast and secreted protein trafficking in P. falciparum 
Live fluorescent images of transgenic parasite lines that express the full-length apicoplast 
trafficking motif (signal sequence and transit peptide) from ACP fused to SFG (A) or just 
the signal sequence of ACP fused to SFG (B). Images are 10 microns long by 10 microns 
wide. 
A) Typical branched structure of the apicoplast in the trophozoite stage of development in 
the red blood cell.  
B) Secreted SFG protein that is mostly accumulated in the parasitophorous vacuole space 
that separates the parasite from the red blood cell. SFG signal observed inside the parasite 





Figure 2-2 CLD:EcDHFR design and analysis of protein trafficking  
A) The first test of a candidate CLD was a destabilization domain containing EcDHFR 
protein with additional N-terminal mutations designed to increase the net positive charge 
near the N-terminus. Lysine mutations in blue increase positive charge; destabilization 
domain mutations are underlined.  
Signal Seq.ACP = Signal sequence from ACP  
GFP = green fluorescent protein 
B) Live fluorescence images of cells expressing the CLD fused to GFP. Cells treated with 
Trimethoprim at 5 μM for 48 hours before imaging.  
C) Immunofluorescence images of fixed cells stained with anti-ACP (apicoplast marker) and 
anti-GFP antibodies in the absence of Trimethoprim. 
Images are 10 microns long by 10 microns wide. 
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Figure 2-3 CLD:MmDHFR design and analysis of protein trafficking  
A) The second test of a candidate CLD was the wild type MmDHFR protein with no 
mutations. 
SFG = Super Folder Green (enhanced GFP) 
B) Live fluorescence images of cells expressing the CLD fused to SFG. Cells treated with 
Trimethoprim at 5 μM for 48 hours before imaging.  
C) Immunofluorescence images of fixed cells stained with anti-ACP (apicoplast marker) and 
anti-GFP antibodies in the absence of Trimethoprim. 





Table 2-1 Transfection log for over expression of DHFR in the apicoplast 
We attempted to express EcDHFR and MmDHFR in the apicoplast of P. falciparum. Each 
protein was transfected with a high (calmodulin) or low (ribosomal L2 protein) strength 
promoter and transfections were considered successful if parasites were able to grow back 
after drug selection with blasticidin. None of the four successfully transfected lines expressed 
the transgene. Expression was evaluated by searching for green fluorescent signal in live 
fluorescent microscopy analysis.  
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Figure 2-4 Amino-terminal structures of DHFR and FKBP 
A) DHFR structure with the first 20 amino acids colored red. The N-terminus is a part of 
the loop domain that binds dihydrofolate. 
B) FKBP structure with the first 10 amino acids colored red. The N-terminus is not buried 
in the core of the protein structure and may be more readily available when the protein is 
destabilized.  
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Design and Evaluation of FK506 Binding Protein as a Candidate 


















 In this chapter we modified the FK506 Binding Protein (FKBP) to engineer a new 
group of candidate conditional localization domains. The first candidate CLD we tested was 
derived from a destabilized FKBP mutant that has been used as a degradation domain in P. 
falciparum. We modified the destabilized FKBP to mimic an apicoplast transit peptide and 
expressed the CLD (CLD:FKBP) fused to a fluorescent cargo protein. We then analyzed the 
localization of the CLD using live fluorescence microscopy. CLD:FKBP trafficked to the 
apicoplast in the absence of the interacting ligand and did not change localization when the 
ligand was added to cell culture media.  
Because CLD:FKBP did not change localization it was not an ideal domain to use 
for our conditional localization system. We hypothesized that CLD:FKBP may be too 
unstable to effectively bind the ligand and change localization in vivo. To investigate this 
hypothesis we purified the CLD:FKBP protein and did thermal shift assays to measure 
thermal stability of the protein. Our results showed that CLD:FKBP is significantly less 
stable than the control destabilized FKBP mutant. This result led us to re-design 
CLD:FKBP to create more stable candidate domains. Our goal in re-designing CLD:FKBP 
was to increase the stability of the domain while also maintaining its ability to traffic to the 
apicoplast under permissive conditions.   
CLD1, CLD2, and CLD3 are re-designed candidate CLDs that contain less severe 
destabilizing mutations than those of CLD:FKBP. We expressed CLD1, 2, and 3 in separate 
P. falciparum transgenic parasite lines fused to a fluorescent cargo protein, and analyzed their 
localization. All three of the candidate CLDs trafficked to the apicoplast in the absence of 
the interacting ligand and changed localization to become secreted when the ligand was 
added to cell culture media. CLD1, 2, and 3 meet the basic trafficking requirements for our 
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apicoplast conditional localization system. We moved forward with an in depth 




 FK506 Binding Protein (FKBP) is a protein folding chaperone that specifically 
functions as a proline cis-trans isomerase1. FKBP structure and function have been studied 
extensively because it is the target of the immunosuppressive compound FK5061–3. FK506 
forms a complex with FKBP that inhibits T-cell activation by blocking the activity of the 
phosphatase Calcineurin, which is required to activate transcription factors that promote in 
T-cell activation4,5. Studies have shown that FKBP has a very high affinity and specific 
binding interaction with FK506, which makes the FKBP/FK506 pair an appealing protein 
and ligand combination for engineering molecular tools6. Both FKBP and FK506 have been 
redesigned to identify mutations or modifications that further enhance their binding affinity7. 
This is appealing because FKBP mutants that bind synthetic ligands more effectively than 
natural ligands are less likely to interfere with endogenous pathways when expressed in the 
cell as a molecular tool. Two FKBP mutant and FK506 derived molecule combinations have 
been used in P. falciparum for conditional export and conditional degradation domain 
molecular tools8–10.  
The conditional export system uses a Conditional Aggregation Domain (CAD) tag to 
control the localization of exported proteins in P. falciparum. The CAD was designed from a 
mutant FKBP protein that binds the synthetic ligand AP21998 more effectively than its 
endogenous ligands 9. The domain consists of four mutant FKBPs that are added as a fusion 
protein tag to the amino terminus of a protein of interest.  In the absence of AP21998, 
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proteins tagged with the CAD aggregate in the endoplasmic reticulum and are blocked from 
being exported. When AP21998 is added to cell culture media, the CADs dissociate and 
allow the protein to be exported across the parasitophorous vacuole membrane into the red 
blood cell cytosol. 
A conditional degradation domain was designed from a mutant FKBP that binds the 
synthetic ligand Shield1 more efficiently than its endogenous binding partners7,11. The 
conditional degradation domain is mutated so that it is unstable in the absence of Shield1 
and causes proteins tagged with the domain to be degraded. When Shield1 is added to cell 
culture media the domain stabilizes so that the tagged protein remains in the cell. The 
conditional degradation domain has been successfully used as a molecular tool in P. 
falciparum to conditionally knock down proteins and show that they are essential for parasite 
development in the erythrocytic cycle 8,12,13. For example, conditional knockdown of the 
calcium-dependent protein kinase 5 (PfCDPK5) revealed that PfCDPK5 is essential for 
schizont egress from the red blood cell12. The cysteine protease Caplain was also 
conditionally knocked down, to show that Caplain is essential for progression from the ring 
to trophozoite stage of parasite development13.  
We designed a candidate CLD from the destabilized FKBP that was used as a 
degradation domain in P. falciparum (CLD:FKBP). CLD:FKBP also binds the synthetic ligand 
Shield1. One drawback of using a Shield1 binding FKBP mutant for our CLD is that Shield1 
has moderate anti-malarial effects when added to cell culture media at high concentrations10. 
Shield1 concentrations above 1 μM cause a delay in trophozoite development10. As a result, 
any molecular tool designed for use in P. falciparum that requires Shield1 –including our 
apicoplast conditional localization system – must be effective at low concentrations of this 
ligand.  
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To test CLD:FKBP as a candidate CLD, we expressed the domain with a fluorescent 
cargo protein so that we could visualize its localization using live fluorescence microscopy. 
Our analysis of protein trafficking by CLD:FKBP revealed that this candidate CLD traffics 
to the apicoplast regardless of the presence of the ligand Shield1. We hypothesized that 
CLD:FKBP may be too unstable to bind Shield1 and change localization in vivo. Additionally, 
we reasoned that if we partially stabilized CLD:FKBP without affecting its ability to traffic to 
the apicoplast, it could ultimately be a successful candidate for our conditional localization 
system.  
To measure the stability of CLD:FKBP we purified the CLD:FKBP protein and 
determined its melting temperature using a thermal shift assay. We compared the melting 
temperature of CLD:FKBP to that of a stable control Shield1-binding FKBP (sbFKBP) and 
a destabilized FKBP (dFKBP) control. CLD:FKBP was significantly less stable and less 
competent to bind Shield1 than the dFKBP control. These data supported our hypothesis 
that CLD:FKBP is too unstable to effectively bind Shield1 in vivo and encouraged us to 
redesign CLD:FKBP to generate more stable mutants that could be successful candidate 
CLDs.  
The redesigned CLD:FKBP proteins – CLD1, CLD2, and CLD3 – have a 
metastable structure that allows them to strike a balance between being unstable enough to 
traffic to the apicoplast under permissive conditions and also maintain the capacity to bind 
Shield1. CLD1, 2 and 3 were our first successful candidate CLDs. They meet the basic 
requirement of trafficking to the apicoplast under permissive conditions (-Shield1) and 
changing localization when Shield1 is added to cell culture media. In our next set of 
experiments described in Chapter 4, we conducted an in depth analysis of the dynamics of 





Design and Expression of CLD:FKBP 
 We reasoned that the CLD should mimic an apicoplast transit peptide under 
permissive conditions to allow it to traffic to the apicoplast. As discussed in previous 
chapters, transit peptides must maintain a net positive charge near the N-terminus. To meet 
this requirement, we mutated a negatively charged glutamic acid at position 6 and an 
uncharged glutamine at position 4 to positively charged lysine residues (FKBPQ4K,E6K). These 
mutations increase the overall charge near the N-terminus of FKBP to +3. Transit peptides 
are unstructured during apicoplast import and formation of structure in the transit peptide 
region blocks import to the apicoplast. To give the CLD structural features that can be 
controlled experimentally, we introduced the destabilizing degradation domain mutation 
(FKBPL107P) to destabilize the protein in the absence of the ligand
8. We hypothesized that the 
destabilized CLD would mimic an unstructured transit peptide and allow the CLD to traffic 
to the apicoplast. When we add the ligand to cell culture media we expect to stabilize the 
structure of the CLD and block the protein from being imported into the apicoplast. Finally, 
the CLD:FKBP protein also contains the Shield1 binding mutation (FKBPF36V), this 
mutation allows CLD:FKBP to bind the synthetic molecule Shield1 more effectively than 
other potential endogenous binding partners in the cell. Each of the mutations introduced to 
create CLD:FKBP are highlighted in Figure 3-1 A.  
The CLD:FKBP sequence was expressed in P. falciparum with an N-terminal signal 
sequence from ACP and the SFG protein at the C-terminus. We also input the CLD:FKBP 
amino acid sequence into the PATS algorithm (the PATS program was discussed in detail in 
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the introduction to Chapter 2) to determine how similar the sequence is to natural P. 
falciparum transit peptides. The PATS program gave CLD:FKBP a score of 0.94, which 
indicates that CLD:FKBP closely mimics the basic sequence features of a P. falciparum transit 
peptide.   
 We analyzed protein trafficking of CLD:FKBP using live fluorescence microscopy 
shown in Figure 3-1 B. In the absence of Shield1 we observed an SFG trafficking pattern 
that is consistent with apicoplast trafficking. The SFG signal forms a branched organelle that 
is distinct from the mitochondrion staining in the trophozoite stage of parasite development 
(Figure 3-1 B top row). We confirmed that CLD:FKBP traffics to the apicoplast by co-
localizing SFG with the apicoplast marker ACP using immunofluorescence assays (A 
representative image is shown in Figure 3-1C). Next, we added 500 nM Shield1 to parasite 
culture media for 48 hours before analyzing protein localization. We did not observe a 
change in SFG localization with this treatment (Figure 3-1 B middle row) so we doubled the 
Shield1 concentration in our next experiment. We still did not observe a significant change 
in localization of SFG after treatment with 1 μM Shield1 (Figure 3-1B bottom row). These 
data show that CLD:FKBP traffics to the apicoplast regardless of the presence of Shield1 
and is not an ideal domain for our conditional localization system. We hypothesized that the 
two N-terminal lysine mutations (FKBPQ4K,E6K) combined with the destabilizing degradation 
domain mutation (FKBPL107P) may have caused CLD:FKBP to be too unstable to effectively 
bind Shield1 and change localization in vivo. In our next set of experiments we tested this 
hypothesis by analyzing the thermal stability of the CLD:FKBP protein purified in vitro. 
 
Analysis of thermal stability of CLD:FKBP 
54 
 We used thermal shift assays to determine the melting temperature of the 
CLD:FKBP protein and compare it to the melting temperature of stable (sbFKBP) and 
unstable (dFKBP) control proteins. In order to get purified proteins for thermal shift assays 
we expressed each FKBP mutant – sbFKBP, dFKBP, and CLD:FKBP – in E. coli and 
purified them from cell lysates using Maltose Binding Protein (MBP) and Histidine tags 
fused to the N-terminus of the protein. We then further purified the FKBP mutants by size 
exclusion chromatography.  
 In the process of purifying the unstable FKBP mutants (dFKBP and CLD:FKBP) 
we encountered some difficulties that we did not encounter when purifying the stable FKBP 
mutant (sbFKBP). We induced expression of CLD:FKBP and dFKBP in E. coli and ran the 
cell lysate over an amylose column to concentrate the proteins with an MBP tag (Figure 3-2 
A, lanes labeled “CLD:FKBP (no TEV)” and b, lane labeled “dFKBP (no TEV)”  ). We 
then cleaved the MBP tag from CLD:FKBP or dFKBP using the Tobacco Etch Virus 
(TEV) protease. At this point we estimate that about 79 % of the CLD:FKBP protein 
precipitated out of solution (Figure 3-2 A lane labeled “P” for pellet in red box). We were 
not able to collect enough protein from the left over soluble fraction (Figure 3-2 A lane 
labeled “S” for soluble in red box) of this experiment to proceed with the thermal shift 
assay. In our next CLD:FKBP protein preparation, we added Shield1 to the TEV cleavage 
step to stabilize the CLD:FKBP protein and help maintain its solubility (Figure 3-2 A green 
box). Under these conditions only about 50 % of the CLD:FKBP protein precipitated out of 
solution (Figure 3-2 A, compare CLD:FKBP in green box in lanes labeled “P” and “S”).  
A similar but less severe result was observed when we purified dFKBP (Figure 3-2 
B). When we did a TEV cleavage assay in the absence of Shield1, and about 66 % of the 
dFKBP protein precipitated out of solution (Figure 3-2 B compare dFKBP in lanes labeled 
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“P” and “S” in red box). In a parallel experiment we added Shield1 to the TEV cleavage 
assay and only 41 % of the dFKBP precipitated (Figure 3-2 B compare dFKBP in lanes 
labeled “P” and “S” in green box). The observation that destabilized FKBP mutants 
precipitate in solution without a stabilizing ligand indicate that both CLD:FKBP and dFKBP 
are significantly less stable than sbFKBP which did not precipitate after TEV cleavage. The 
higher percentage of precipitated protein in the CLD:FKBP preparation suggests that 
CLD:FKBP is even less stable than dFKBP.         
 We used Thermal Shift Assays to determine the melting temperature of the stable 
FKBP mutant purified without Shield1, and the unstable FKBP mutants purified with 
Shield1. Because we had to add Shield1 to the preparation to solubilize the dFKBP and 
CLD:FKBP proteins, we only compared the melting temperatures from the assays done in 
the presence of Shield1 in Table 3-1. Our analysis shows that dFKBP is 14.6 °C less stable 
than sbFKBP, while CLD:FKBP is 20.3 °C less stable. This result suggests that one or both 
of the N-terminal lysine mutations (FKBPQ4K,E6K) further destabilize the CLD:FKBP protein 
so that it is less competent to bind Shield1 than dFKBP. These data also support our 
hypothesis that CLD:FKBP may be too unstable to effectively bind Shield1 in vivo and 
change localization. We redesigned CLD:FKBP and tested three new candidate CLDs that 
are more stable mutants of the original CLD:FKBP in the next section.   
 
Design and Expression of CLD1, CLD2, and CLD3 
 Our goal in designing the next group of candidate CLDs (CLD1, CLD2 and CLD3) 
was to add back some stability to the CLD:FKBP protein, without losing the ability to traffic 
to the apicoplast. We reverted the destabilizing proline mutation at position 107 (FKBPL107P) 
back to a leucine residue to enhance stability of the protein and tested three different 
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arrangements of lysine mutations near the N-terminus of the CLD to determine which 
mutations are most important for apicoplast trafficking. CLD1 has a mutation at residue 4 to 
convert an uncharged glutamine to a positively charged lysine (FKBPQ4K); this increases the 
overall positive charge near the N-terminus +1. CLD2 has a mutation at residue 6 to convert 
a negatively charged aspartic acid to lysine (FKBPE6K) and increase the overall charge +2. 
Finally, CLD3 has a mutation at both residues four and six (FKBPQ4K,E6K) to increase the net 
positive charge +3. A summary of FKBP mutations made to generate CLD1, 2, and 3 is 
show in Figure 3-3. Based on the thermal stability analysis described in the previous section, 
we hypothesized that these lysine mutations might also slightly destabilize FKBP and allow it 
to traffic to the apicoplast when there is no Shield1 present. Because these mutations are 
likely not as severe as the degradation domain mutation of CLD:FKBP we expect that 
CLD1, 2, and 3 should also be more competent to bind Shield1 in vivo.   
We expressed CLD1, 2 and 3 in separate parasite lines using the previously described 
signal sequence and SFG cargo protein that were also expressed with CLD:FKBP and allow 
us to monitor protein localization using fluorescent microscopy. The “-” Shield1 rows in 
Figure 3-4, 3-5, and 3-6 show trafficking of CLD1, 2 and 3 respectively, with no Shield1 
added to the culture. A representative image at each development stage in the red blood cell 
– ring, trophozoite, and schizont - is shown and the pattern of fluorescence observed in 
these rows is consistent with previous reports of apicoplast trafficking14. The apicoplast is 
typically identified in live fluorescence images as a branched organelle that is distinct from 
the mitochondrion staining in the trophozoite stage. The apicoplast however, is closely 
associated with the mitochondria at all stages of development in the red blood cell and the 
two organelles occasionally touch in the images shown14.  
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The “+” Shield1 rows in Figure 3-4, 3-5, and 3-6 show trafficking of CLD1, 2, and 3 
respectively, after cells were treated with 500 nM Shield1 for 24 hours. The pattern of 
fluorescence in these rows is consistent with the protein being secreted. Proteins that are 
secreted from the cell accumulate in the parasitophorous vacuole space that separates the 
parasite from the red blood cell cytosol 14. In many of the images collected from CLD1, 2, 
and 3, SFG appears to accumulate in the parasitophorous vacuole space and the digestive 
vacuole after the addition of Shield1. This pattern of fluorescence is similar the trafficking of 
the resident digestive vacuole protease Dipeptidyl Amino Peptidase I (DPAP1)15. DPAP1 is 
secreted into the parasitophorous vacuole space where it accumulates before moving to the 
digestive vacuole, presumably through the cytostomes. The CLD may follow a similar 
pattern when it is secreted into the parasitophorous vacuole space, and get taken back into 
the cell to the digestive vacuole through the cytostome. This experiment shows that CLD1, 
2, and 3 all meet the basic trafficking requirements for our conditional localization system.  
 
CONCLUSIONS AND DISCUSSION 
 
 Our studies to engineer a CLD from FKBP suggest that there must be a balance in 
the in the stability of the CLD. The CLD must be unstable enough to mimic an unstructured 
transit peptide and traffic to the apicoplast while also maintaining enough stability to bind 
Shield1 in vivo and change localization.  
CLD:FKBP contained three potentially destabilizing mutations (FKBPQ4K, E6K, L107P) 
and was less stable than the dFKBP degradation domain used in the conditional degradation 
system(Table 3-1). This suggests that one or both the amino-terminal lysine mutations in 
CLD:FKBP further destabilize the domain, and make it less competent to bind Shield1 in 
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vivo. Because CLD:FKBP is not able to effectively bind Shield1, it trafficked to the apicoplast 
even when Shield1 was added to cell culture media (Figure 3-1) and could not be used for 
our conditional localization system. 
We redesigned CLD:FKBP to increase its overall stability and competence to bind 
Shield1. CLD1, 2, and 3 each contain one or both of the lysine mutations at residues 4 and 6 
from CLD:FKBP and no destabilizing degradation domain mutation (Figure 3-3). These 
lysine mutations increase the net positive charge near the N-terminus and our thermal 
stability analysis suggests that they also slightly destabilize the protein. In addition to our 
thermal stability analysis of CLD:FKBP, another indication that the amino terminal lysine 
mutations we made at residues 4 and 6 are slightly destabilizing can be found in the original 
publication describing how the FKBP degradation domain was generated. The degradation 
domain was selected from a screen of randomly mutagenized FKBPs11. The FKBP mutants 
were phenotypically screened for proteins that were unstable without Shield1 and stabilized 
when bound to Shield1. In the supplementary information for this study there is a list of all 
of the destabilizing mutation combinations identified in this screen. We found the FKBPE6K 
mutation appeared twice on this list of destabilizing FKBP mutations. And a similar 
mutation to FKBPQ4K in terms of charge, which is FKBPQ4R, was also identified twice in the 
screen of destabilizing FKBP mutations. We tested the redesigned candidate CLDs in P. 
falciparum and all three of the candidate domains appear to traffic to the apicoplast in the 
absence of Shield1 and change localization to become secreted when Shield1 is 
supplemented in cell culture media (Figure 3-4, 3-5, and 3-6).  
FKBP has some features that may have made it a better candidate CLD than DHFR. 
The first feature is its small size compared to DHFR. FKBP is 108 amino acids long while 
both of the DHFR proteins tested in Chapter 2 were over 150 amino acids long. Secondly, 
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FKBP has been modified to interact more efficiently with the synthetic ligand Shield1 than 
any of its endogenous binding partners in the cell. This gives FKBP an advantage over 
DHFR because it should not bind cellular ligands that could affect protein stability or 
apicoplast biochemistry.  
In our next group of experiments (Chapter 4) we conducted an in depth analysis of 
protein trafficking and thermal stability of CLD1, 2, and 3. We were interested in 
determining whether CLD1, 2 and 3 were equal in their trafficking capacity to both the 
apicoplast and secreted compartment or if they differed in their ability to traffic to one 
compartment or the other. This information is valuable to determine how each CLD can be 
best used in validation studies to tag specific proteins of interest and answer questions about 




Generation of plasmid constructs 
 The human FKBP gene with Shield1 binding mutation 8 was PCR amplified using 
forward primers that contain nucleotide changes to produce lysine mutations at residues 4, 6, 
or both (to generate CLD1, 2 or 3 respectively). NdeI.FKBPq4k.for was used to generate 
CLD1, NdeI.FKBPe6k.for was used for CLD2, and NdeI.Fkkfor was used for CLD3. One 
reverse primer (FKBP.P107L.BglII.rev) was used to amplify the FKBP gene without the 
destabilizing degradation domain mutation (FKBPL107P) for CLD1, 2, and 3. NdeI.Fkkfor 
and FKBP.BglII.rev were used to amplify CLD:FKBP. FKBP inserts were then digested 
using NdeI and BglII and ligated into cloning vectors (GeneArt) that contained the 
synthesized signal sequence from the ACP gene and the super folder green sequence 16. The 
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CLD sequences were then ligated into a modified pLN 17 vector for parasite transfection that 
contained the lower strength ribosomal L2 protein promoter 18 instead of the calmodulin 
promoter.  
Plasmids used for protein expression in E. coli were generated by PCR amplifying the 
human FKBP gene with the Shield1 binding mutation 8 using a forward primer that contains 
nucleotide changes to produce lysine mutations at residues 4 and 6 to generate CLD:FKBP 
(Fkk.EcoRI.LIC.for). The sbFKBP and dFKBP genes were amplified using the 
Fqe.EcoRI.LIC.for forward primer that does not generate any mutations at the N-terminus. 
A reverse primer that contains the destabilizing degradation domain mutations 
(FKBP.P107.HindIII.LIC.rev) was used to amplify the CLD:FKBP and dFKBP genes and a 
reverse primer that does not contain the FKBPL107P mutation was used to amplify sbFKBP 
(FKBP.P107L.HindIII.LIC.rev). PCR amplicons were then inserted into the pMALcHT 19 
E. coli expression vector using ligase independent cloning with T4 DNA polymerase. DNA 
sequences were confirmed by sequencing after insertion.  
 
Protein expression and purification 
 Plasmids pMALcHT-sbFKBP, pMALcHT-dFKBP, pMALcHT-CLD:FKBP were 
transformed into BL21-Star (DE3) cells and co-transformed with the pRIL plasmid isolated 
from BL21-CodonPlus-RIL cells 20. These cells produce a protein product fused to an 
amino-terminal MBP tag followed by a Tobacco Etch Virus (TEV) protease cleavage site 
and a six-histidine tag. Cells were pelleted and then resuspended in lysis buffer (20 mM 
HEPES pH 7.5, 500mM NaCl, 1 mg/ml DNAse I, and 100 mg/ml Lysozyme). Cell lysates 
were then sonicated at amplitude of 45% for a total of six minutes broken into 2-minute 
intervals of 0.5 seconds on and 0.5 seconds off. After sonication cell lysates were filtered 
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through a 0.45 micron filter before purification.  All constructs were then purified using an 
amylose column and eluted with 100 mM maltose followed by cleavage with TEV protease 
at room temperature overnight in the presence of 1 mM DTT and 0.5 mM EDTA. The 
cleavage product was extensively dialyzed into 20 mM HEPES pH 7.5 and 500 mM NaCl 
and purified from the MBP tag via nickel-affinity chromatography using a His Trap HP 
column (GE Life Sciences). Appropriate fractions were collected and further purified by size 




Cells were fixed, permeabilized and reduced using the same protocol described in the 
Methods section of Chapter 2. Before applying primary antibodies, cells were washed in PBS 
and then incubated with appropriate antibodies overnight at 4 °C [rat polyclonal αACP 
1:2000, raised against the P. falciparum antigen; rabbit polyclonal αGFP 1:10,000 raised 
against recombinant GFP protein]. The next day, cells were washed three times in PBS and 
then once in 3 % BSA. Appropriate secondary antibodies  [goat αrabbit AlexaFluor 594 
1:1000 (Life Technologies); donkey αrat AlexaFluor 488 1:3000 (Life Technologies)] 
 
Thermal shift assay 
Stability of the different FKBP constructs was determined using a thermal shift assay 
as previously described 21 with minor modifications. RT-PCR tube strips (Eppendorf) were 
used to hold 30 μL mixtures containing final concentrations of 40 μM (0.5 mg/mL) FKBP 
mutant and 200 μM Shield1. The Shield-1 compound (dissolved in 100% ethanol) was first 
added to the PCR tube to set up the reaction mixture and the solvent was then allowed to 
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evaporate at room temperature. Shield1 was re-suspended in buffer (HEPES pH 7.4 and 100 
mM NaCl) followed by addition of FKBP mutant and 1 μL of Sypro Orange (Sigma, 
product no. S-5692). The reaction mixture was incubated in a RT-PCR machine (Applied 
Biosystems, Step One Plus Real-Time PCR System) for 2 min at 20 °C followed by an 
increase in temperature of 0.2 °C per 10 s until a final temperature of 80 °C. Fluorescence 
was monitored in the Step One Plus Real-Time PCR system using a TAMRA filter in which 
an increase in Sypro Orange fluorescence (excitation: 480 nm, emission: 568 nm) was 
observed upon thermal denaturation of FKBP mutant. Temperature and melt curve data 
points were exported from the StepOne v2.3 software program and analyzed in Excel to 
determine the melting temperature. All thermal shift assays were done with triplicate 
technical replicates for the indicated number of biological replicated given in figure legends.  
Live cell imaging 
 Cells were stained for live fluorescence imaging using the same protocol described in 
Chapter 2. Samples were then taken to the Zeiss microscope for imaging.  
Quantification of Protein Bands 
 The quantification of protein bands on the gels presented in Figure 3-2 was done 
using the ImageJ software program to estimate the amount of protein in each lane based on 
intensity of the gel staining with Simply Blue Safe Stain (Invitrogen) 22. Briefly, the intensity 
of the FKBP bands in the soluble and pelleted lanes was added to calculate the total intensity 
and then the intensity of the pelleted lane was divided by the total intensity to get the percent 
of FKBP that precipitated in each sample.   
 
 Parasite transfection and culture methods are the same as for Chapter 2 
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Figure 3-1 CLD:FKBP design and analysis of protein trafficking 
A) We generated a transgenic parasite line that expresses a verified signal sequence from 
ACP fused to CLD:FKBP and super folder green (SFG). The N-terminal sequence of 
CLD:FKBP is shown. Lysine mutations in blue increase positive charge; destabilization 
domain mutation is in bold; Shield1 binding mutation is underlined. The overall change in 
charge near the N-terminus is listed in the right column.   
B) Live fluorescence images of cells expressing the transgene shown in part A. Cells in the 
top row have not been treated with Shield1. Cells in the second row were treated with 500 
nM for 48 hours and cells in the third row were treated with 1 μM Shield1 for 24 hours 
before imaging. Images are 10 μm long by 10 μm wide. 
C) Immunofluorescence images of fixed cells stained with anti-ACP (apicoplast marker) and 
anti-GFP antibodies in the absence of Shield1. Images are 10μm long by 10μm wide. 
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 Figure 3-2 Analysis of protein precipitation from unstable FKBP mutants  
A) An MBP tagged CLD:FKBP protein was expressed in E. coli and purified from cell 
lysates. The far left lane on both gels shows purified MBP-CLD:FKBP eluted from an 
amylose column. The protein solution was treated with TEV protease to separate the 
CLD:FKBP from MBP. At this point, CLD:FKBP precipitated and we pelleted the insoluble 
fraction. The boxes on both gels show the amount of CLD:FKBP protein in the pellet (“P”) 
and supernatant (“S”) after the TEV cleavage assay. The red box shows a TEV cleavage 
assay done without Shield1, and the green box shows the assay done in with Shield1 added at 
approximately 3 Shield1 molecules per CLD:FKBP protein.  
B) The destabilized FKBP (dFKBP) was also expressed in E. coli and purified from cell 
lysates. The far left lane shows purified MBP-dFKBP eluted from an amylose column. The 
dFKBP also precipitated after cleavage with the TEV protease and the insoluble fraction was 
pelleted. The red box shows a TEV cleavage assay done without Shield1, and the green box 
shows the assay done in with Shield1 added at approximately 3 Shield1 molecules per 
dFKBP protein. 
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Table 3-1 Analysis of thermal stability of CLD:FKBP 
Melting temperatures determined using Thermal Shift Assays. CLD:FKBP and dFKBP 
could not be purified at high concentrations without adding Shield1 during purification to 
stabilize the protein so only +Shield1 melting temperatures (Tm) are compared in this 
analysis. Melting temperatures are shown with standard deviations calculated from triplicate 
biological replicates.  
Derivative reporter plots show representative data curves generated for each protein.  
sbFKBP = Shield1 binding FKBP 
dFKBP = destabilized FKBP 





Figure 3-3 Three candidate CLDs re-designed from the original CLD:FKBP 
sequence 
Test constructs for evaluation of three CLDs that were redesigned from the original 
CLD:FKBP sequence. The N-terminal sequence of CLD1-3 varies as shown. Lysine 
mutations in blue increase positive charge and the overall changes in charge near the N-
terminus are listed in the right column. Shield1 binding mutation is underlined and the 
destabilizing degradation domain mutation is in bold in CLD:FKBP, but has been reverted 







Figure 3-4 Analysis of protein trafficking for CLD1 
Live images of transgenic parasites lines expressing CLD1. The rows labeled “-” are cells 
that have not been treated with Shield1 and rows labeled “+” are cells that have been treated 
with 500 nM Shield1 for 24 hours. The development stage of each parasite is estimated 
based on the number of nuclei and the size of the parasite relative to the red blood cell. 








Figure 3-5 Analysis of protein trafficking for CLD2 
Live images of transgenic parasites lines expressing CLD2. The rows labeled “-” are cells 
that have not been treated with Shield1 and rows labeled “+” are cells that have been treated 
with 500 nM Shield1 for 24 hours. The development stage of each parasite is estimated 
based on the number of nuclei and the size of the parasite relative to the red blood cell. 








Figure 3-6 Analysis of protein trafficking for CLD3 
Live images of transgenic parasites lines expressing CLD3. The rows labeled “-” are cells 
that have not been treated with Shield1 and rows labeled “+” are cells that have been treated 
with 500 nM Shield1 for 24 hours. The development stage of each parasite is estimated 
based on the number of nuclei and the size of the parasite relative to the red blood cell. 
Images are 10 μm long by 10 μm wide 
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Table 3-2 Primers used to generate CLD sequences for expression in P. falciparum 
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Evaluation of Protein Trafficking by Conditional Localization Domains 


















 This chapter describes our analysis of protein trafficking dynamics for CLD1, 2, and 
3. We analyzed protein trafficking by CLD1, 2, and 3 in immunofluorescence images of cells 
stained with antibodies to track the location of the cargo protein (SFG) in the presence and 
absence of the interacting ligand (Shield1). Our analysis revealed that CLD1 has a leaky 
apicoplast trafficking phenotype, CLD3 showed a slight tendency to traffic to the apicoplast 
in the presence of Shield1, and CLD2 trafficked most efficiently to both the apicoplast and 
secreted compartment.  
We hypothesized that CLD1’s leaky apicoplast trafficking phenotype could be caused 
by a higher level of protein stability compared to CLD2 or 3. To investigate this hypothesis 
we analyzed the thermal stability of CLD1, 2 and 3 using thermal shift assays to determine 
the melting temperature of each protein. Our analysis showed that as expected, CLD1 has a 
higher thermal stability than CLD2 or 3. CLD1’s higher stability likely prevents it from 
sampling the unfolded state as often as CLD2 or 3 and causes it to be less efficiently 
trafficked to the apicoplast.  
We also titrated Shield1 concentrations to determine the relative sensitivity of CLD1, 
2, and 3 to low concentrations of the Shield1 ligand. We found that CLD1 was the most 
sensitive to low concentrations of Shield1. This is consistent with our thermal stability 
analysis, which showed that CLD1 is also the most stable domain, and likely the most 
competent to bind Shield1 in vivo. CLD2 and 3 have similar levels of sensitivity and were less 
sensitive to low concentrations of Shield1 than CLD1. All three of the CLDs respond to 
concentrations of Shield1 well below 1 μM.  
Our analysis showed that CLD2 has the most efficient trafficking characteristics and 
will likely be ideal for use in most validation studies of our conditional localization system. 
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We further investigated the timing of localization change and the effect of higher 
concentrations of Shield1 on CLD2 trafficking. These studies showed that secretion is nearly 
complete at 24 hours with 500 nM Shield1 added to cell culture media. Although CLD1 and 
3 did not have the most efficient trafficking characteristics, they may still be useful in studies 
of certain protein where exclusion of protein from one compartment or the other is 
desirable. This analysis of the trafficking dynamics of CLD1, 2, and 3 will be used to guide 




 The goal of this study was to gain a better understanding of how CLD1, 2, and 3 
differ in their ability to control protein trafficking. The development and initial studies of 
these CLDs are described in detail in Chapter 3. In this chapter we further characterized 
each domain to quantitatively analyze the trafficking efficiency and Shield1 sensitivity of each 
CLD. We also purified each CLD protein from E. coli to measure thermal stability of the 
domains.  
 To study protein trafficking we did a co-localization analysis that compared the 
localization of the CLD trafficked cargo protein (SFG) to the apicoplast marker ACP. We 
calculated co-localization statistics for each cell using the ImageJ image processing software 
developed by the National Institutes of Health1. In the absence of Shield 1 we expect a high 
level of co-localization between SFG and ACP to confirm the apicoplast trafficking pattern 
of CLD1, 2, and 3 observed in live fluorescence images (Chapter 3; Figures 3-4, 3-5, and 3-
6). When Shield1 is added to cell culture media we expect to see a drop in co-localization as 
the SFG protein is diverted from the apicoplast and is secreted from the cell. 
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The Pearson’s Correlation Coefficient (PCC) is a measure of co-localization that is 
often reported in image analysis studies2,3. The PCC is modeled visually by plotting the 
intensities of the two fluorochromes being analyzed (for example TRITC and FITC) on the 
x and y-axis of a scatter plot (Figure 4-1). The PCC estimates how well the relationship 
between two fluorochromes plotted on an intensity scatter plot matches a linear 
approximation. When there is co-localization between the two fluorochromes, a positive 
linear relationship is observed on the intensity scatter plot (Figure 4-1 A) and the PCC is 
near 1. When there is not significant overlap between the fluorochromes being analyzed 
there is a negative linear or no relationship on the intensity scatter plot (Figure 4-1 B) and 
the PCC value is closer to -1 or 0.  
The PCC is impacted by the average intensity of the two fluorochromes analyzed. 
When there is a significant difference in average intensity between two fluorochromes, the 
PCC value tends to be lowered as data points on the scatter plot are skewed towards the 
more intense fluorochrome’s axis; this decline in PCC value occurs even when there is 
significant co-localization observed in the images of the two channels analyzed3. In our co-
localization data set we analyzed two proteins that are expressed from different promoters. 
The SFG protein is expressed from the ribosomal L2 protein promoter and ACP is 
expressed from its endogenous promoter. This caused the average intensity for the SFG and 
ACP channels to be quite different in some of our data. To avoid the effect of intensity on 
the PCC calculation, we analyzed the Mander’s Overlap Coefficient (M1) instead of the PCC 
value4. In our studies, M1 measures the fraction of intensities from the SFG channel 
(TRITC) that overlap with intensities from the ACP channel (FITC). M1 is not affected by 
the average intensity of the channels because it counts all SFG intensities for which the 
intensity in the ACP channel is above zero equally3.  
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An example of this difference between PCC and M1 calculations is shown in Figure 
4-1 C. The intensity scatter plot in Figure 4-1 C represents the image of the cell to its right. 
For this cell, the average intensity in the FITC channel is higher than the average intensity in 
the TRITC channel. Although the ACP and SFG proteins appear to be mostly co-localized 
in the image, the PCC value calculated for this cell is lower than the M1 value because of the 
skewing of the intensities towards the FITC axis. For images like this one where the average 
intensity of the two channels analyzed is not equal, the M1 value more accurately reflects the 
visual co-localization observed between the ACP and SFG proteins because it does not take 
the average intensity into account. Although the M1 value is not affected by differences in 
average intensity, it is sensitive to high levels of background intensity or noise in the image. 
The ImageJ software however, allows users to manually set thresholds to eliminate 
background intensities from the M1 calculation and setting appropriate intensity thresholds 
for each image reduces the effect of noise on the M1 calculation.  
We calculated M1 values to evaluate the level of co-localization between SFG and 
ACP for CLD1, 2, and 3 in the presence and absence of the interacting ligand, Shield1. 
Previous studies have shown that correct timing of expression is important for trafficking of 
proteins to secretory organelles in P. falciparum5,6. To investigate whether timing of expression 
might have an effect on CLD trafficking we broke the co-localization analysis data up by 
developmental stage (ring, trophozoite, or schizont) and analyzed trafficking to the 
apicoplast and secreted compartment. We did not detect strong trends towards a lowered 
trafficking efficiency at any particular stage but our co-localization analysis did reveal that 
CLD1 has a leaky apicoplast trafficking phenotype compared to CLD2 or 3. We 
hypothesized that CLD1’s leaky apicoplast trafficking may be because CLD1 has a higher 
stability level than CLD 2 or 3, and we investigated this hypothesis by analyzing the stability 
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of each CLD protein using thermal shift assays. Our thermal stability analysis showed that 
CLD1 is more stable than CLD2 or 3 and this likely causes CLD1 to traffic to the apicoplast 
less efficiently than CLD2 or 3. As discussed in previous chapters, transit peptides must be 
unstructured to traffic to the apicoplast, and the destabilization of the CLD is what allows 
the domain to mimic this feature of transit peptides under permissive conditions.  
Finally, we were interested in estimating the lower limit of Shield1 effectiveness for 
each CLD. Given that Shield1 is toxic at high concentrations, it may be ideal to use the 
lowest effective concentration of Shield1 in future experiments. We titrated down the 
concentration of Shield1 and evaluated the localization of CLD1, 2, and 3 at each 
concentration. We found that CLD1 is the most sensitive to low concentration of Shield1, 
while CLD2 and 3 are not as sensitive to low concentrations of Shield1. The analyses 
presented in this chapter will be used to help determine which CLD is most appropriate to 




Analysis of protein trafficking by CLD1, CLD2, and CLD3 
Immunofluorescence assays and calculation of M1 values  
 To measure the trafficking efficiency of CLD1, 2 and 3 we did a co-localization 
analysis of fixed cells co-stained with antibodies against the apicoplast marker ACP and the 
CLD trafficked SFG protein. We analyzed images from untreated cell samples or cells that 
were synchronized and then treated with 500 nM Shield1 for 72 hours before staining. For 
CLD1 we observed only partial co-localization between SFG and ACP (Figure 4-2 A; top 
panel); some of the CLD1 trafficked SFG protein appears to accumulate in the 
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parasitophorous vacuole space in addition to the apicoplast. This observation is consistent 
with a leaky apicoplast trafficking phenotype for CLD1. We observed close co-localization 
however, between SFG and ACP in images of untreated cells expressing CLD2 or CLD3 
(Figures 4-3 A, and 4-4 A; top panel). Analysis of immunofluorescence images collected after 
Shield1 treatment show that SFG accumulates in the parasitophorous vacuole space and 
little to no co-localization is observed between SFG and ACP for all three CLDs (Figures 4-
2 A, 4-3 A, and 4-4 A; bottom panel). Some of the SFG protein in cells treated with Shield1 
is observed in the cell but not in the apicoplast, this protein is presumed to be in the 
secretory pathway, en route to be secreted from the cell.    
We collected images of cells from a minimum of two independent 
immunofluorescence assays done in the presence or absence of Shield1 for each CLD. We 
then calculated M1 values for each cell and summarized the data points on the graphs shown 
in Figures 4-2 B, 4-3 B, and 4-4 B. In the absence of Shield1 CLD2 and 3 have M1 values 
near one, indicating that the ACP and SFG proteins are co-localized.  After the addition of 
Shield1, the average M1 values of CLD2 and CLD3 declined due to a change in the 
localization of SFG so that its intensities no longer overlap with ACP (Figures 4-3 B and 4-4 
B; compare “0 nM Shield1” graph to “500 nM Shield1” graph). For CLD1, the M1 values 
calculated in the absence of Shield1 were not as high as for CLD2 and 3. This was expected, 
because of the leaky apicoplast trafficking observed in immunofluorescence images of CLD1 
expressing cells. When we added Shield1 to the assay, the M1 values for CLD1 declined, but 
the difference was not as significant as was observed for CLD2 and 3 (Figures 4-2 B; 
compare “0 nM Shield1” graph to “500 nM Shield1” graph). 
  Although the calculated M1 values for CLD1 in the absence of Shield1 are low, we 
believe that CLD1 does traffic some protein to the apicoplast because of the live fluorescent 
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images that show a characteristic apicoplast trafficking pattern for CLD1 (Figure 3-4). We 
also consistently observed a portion of SFG protein co-localized with ACP in images of 
parasites expressing CLD1 in the absence of Shield1. The leaky apicoplast trafficking 
phenotype of CLD1 is only evident in immunofluorescence images of fixed cells and is not 
discernable in live fluorescence images (compare live images in Figure 3-4 to 
immunofluorescence images in Figure 4-2 A). Secondary antibody staining enhances 
detection of SFG protein in immunofluorescence images and this enhancement could be 
what allows us to detect small amounts of SFG protein that is secreted by CLD1 in the 
absence of the interacting ligand.  
 
Development of protein trafficking controls and comparison of M1 values 
 We compared the M1 values calculated for CLD1, 2, and 3 to those calculated from 
trafficking controls also expressed in parasites. As a control for apicoplast trafficking we 
expressed the signal sequence and transit peptide from ACP fused to SFG. This parasite line 
constitutively traffics SFG to the apicoplast.  For a secreted trafficking control we expressed 
only the signal sequence from ACP fused to SFG. This parasite line constitutively secretes 
the SFG protein.  Figure 4-5 A shows immunofluorescence images of both of the parasite 
lines that express these trafficking controls. We did two immunofluorescence assays for each 
of the trafficking controls and calculated M1 values to analyze co-localization between the 
apicoplast marker ACP and the SFG protein (M1 values for controls are graphed in Figure 4-
5 B).  
We compared the M1 values calculated for the apicoplast trafficking control to those 
calculated for CLD1, 2, and 3 in the absence of Shield1. This comparison (Shown in Figure 
4-6 A) revealed that CLD2 traffics SFG to the apicoplast at levels most similar to the 
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apicoplast trafficking control. As expected, CLD1 has the most leaky apicoplast trafficking 
and CLD3 traffics to the apicoplast at levels similar to CLD2. We also compared the M1 
values calculated for the secreted trafficking control to those calculated for CLD1, 2, and 3 
in the presence of Shield1 (Also shown in Figure 4-6 A). The M1 values calculated for CLD1 
and 2 were not significantly different form the secreted trafficking control. Slightly higher M1 
values were calculated for CLD3 however, when compared to the secreted trafficking 
control.   
The average M1 values calculated for the apicoplast and secreted trafficking controls 
were used to normalize the M1 values for CLD1, 2, and 3. We compared the normalized M1 
values for each CLD in the presence and absence of Shield1 in Figure 4-6 B. We calculated a 
100 % decline in M1 values after addition of Shield1 for the CLD2 trafficked protein. CLD1 
had an 88 % decline and CLD3 had a 94 % decline in M1 values after Shield1 was added to 
cell culture media.  
Finally, we broke the normalized M1 values down by developmental stage of the 
parasite in the red blood cell (ring, trophozoite, or schizont). We then analyzed protein 
trafficking for CLD1, 2, and 3 at each developmental stage in the presence and absence of 
Shield1 (Figure 4-7). We did not observe any strong trends of mislocalization at any specific 
stage of parasite development. There was a slight decline in M1 values of schizonts for 
apicoplast trafficked CLD2 and 3 (- Shield1), which could be due to a smaller number of 
schizonts analyzed as compared to rings or trophozoites. Also, this decline in M1 values of 
schizonts for CLD2 and 3 is not significantly different from the M1 values calculated for 
schizonts from the apicoplast trafficking control parasite line.  
 
Further characterization of CLD2  
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 Based on our co-localization analysis, CLD2 traffics to the apicoplast and secreted 
compartment at levels most similar to the trafficking controls. This suggests that CLD2 has 
optimal trafficking characteristics to both compartments and may be ideal for use in future 
validation studies. We therefore, further characterized protein trafficking by CLD2. In Figure 
4-8 A we analyzed cells treated with 500 nM Shield1 at an earlier time point and found that 
the decline in M1 values is similar at 24 and 72 hours. We also looked at the effect of 
doubling the concentration of Shield1 on CLD2 secretion in Figure 4-8 B. There was no 
significant difference in the level of secretion at 500 nM and 1 μM Shield1. These studies 
suggest that the change in localization by CLD2 is reasonably complete after 24 hours of 
treatment with 500 nM Shield1.  
 
Analysis of stability of CLD1, CLD2, and CLD3 
 We investigated the thermal stability of the CLD proteins to determine how stability 
of the CLD affects trafficking. Our hypothesis was that CLD1’s leaky apicoplast trafficking 
phenotype, may be caused by a higher stability of the CLD1 protein compared to CLD2 or 
3. We reasoned that a more stable CLD1 protein would be less able to mimic the 
unstructured feature of transit peptides. To investigate this hypothesis, we purified CLD1, 2, 
and 3 proteins for thermal shift assay analysis to determine the melting temperature of each 
protein.  
We compared the melting temperature of the CLDs to the stable Shield1 binding 
FKBP mutant (sbFKBP). Our first observation from this experiment was that the 
destabilized CLD2 and CLD3 proteins could not be purified at concentrations high enough 
for thermal shift assays without adding Shield1 during protein purification. This suggests that 
CLD2 and 3 are more destabilized than CLD1 without a binding ligand.  Because of this 
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feature of the purification process for these CLD proteins, only the assays done with Shield1 
present are comparable. Table 4-1 shows that the melting temperatures of CLD2 and 3 are at 
least 3.8 °C less than the sbFKBP, while CLD1 is only 0.3 °C less. This confirms our 
hypothesis that CLD1 is more stable than CLD2 or 3. This analysis also revealed that the 
charge reversal mutation at residue six (FKBPE6K) has a more destabilizing effect than the 
mutation at residue four (FKBPQ4K) since Tm values for sbFKBP and CLD1 are 
approximately equal and adding the Q4K mutation to CLD2 – to generate CLD3 – does not 
significantly change the melting temperature of the CLD. 
 In order to get an idea of whether the destabilized CLD proteins might be vulnerable 
to degradation, we compared their melting temperature to that of the published degradation 
domain FKBP mutant (dFKBP) 7. dFKBP is destabilized without Shield1, which causes 
proteins tagged with dFKBP to be degraded. We purified dFKBP, and as discussed in 
Chapter 3, this protein could not be purified at high concentrations without adding Shield1 
during protein purification. The difference in Tm between dFKBP and sbFKBP was much 
larger than for any of the 3 CLDs. This suggests that the CLDs are unlikely to be degraded 
without Shield1 since they are at least 10 degrees more stable than the degradation domain 
and they are also trafficked through the secretory pathway where they do not interact with 
the proteasome in the cytosol.   
   
Analysis of sensitivity of CLD1, CLD2, and CLD3 to Shield1   
 In our next set of experiments we titrated down the concentration of Shield1 to 
investigate the limit of sensitivity for each CLD. We added 5, 25, 125, or 500 nM Shield1 to 
cultures for 72 hours before live fluorescence imaging analysis. Because this experiment was 
done using live fluorescence imaging we did not calculate a quantitative number of parasites 
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with a secreted phenotype at each concentration but the images shown are representative 
images of the cells at each concentration. Figure 4-9 A shows that CLD1 was secreted at the 
lowest concentration of Shield1 added (5 nM Shield1).  This is consistent with the thermal 
stability analysis from Table 4-1, showing that CLD1 is the most stable domain, and thus the 
most competent to bind Shield1 in vivo. CLD2 and 3 have similar levels of sensitivity to 
Shield1 and secrete some protein at concentrations as low as 25 nM (Figure 4-9 B and C). 
This is also consistent with thermal stability data showing that CLD2 and 3 have similar 
melting temperatures. CLD3 however, exhibits a partially secreted phenotype at 25 nM 
Shield1 while CLD2’s secretion at this concentration is more complete. This slight difference 
between the responsiveness of CLD2 and 3 could be because of the difference in net 
positive charge near the N-terminus of the two proteins. Since CLD3 has a more positively 
charged N-terminus, it may be more inclined to traffic to the apicoplast in the presence of 
low concentrations of Shield1.  
 
CONCLUSIONS AND DISCUSSION 
 
 This chapter describes our characterization of the protein trafficking dynamics of 
CLD1, 2 and 3. Figure 4-10 summarizes the main analyses of CLD1, 2, and 3 that were 
presented in this chapter. The order of the domains in Figure 4-10 shows how the CLDs 
behaved relative to each other for each analysis. Co-localization analysis revealed that CLD1, 
2, and 3 do not traffic equally well to the apicoplast and secreted compartments (co-
localization data from figures 4-2, 4-3, 4-4, 4-5, and 4-6 is summarized Figure 4-10 A). Most 
notably, CLD1 has a leaky apicoplast trafficking phenotype that was observed as partial co-
localization in immunofluorescence images and reflected in the lower M1 values calculated 
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for CLD1 compared to CLD2 or 3. We investigated whether the leaky apicoplast trafficking 
phenotype of CLD1 is due to a higher level of protein stability compared to CLD2 or 3, by 
measuring the melting temperature of each CLD protein and comparing them to stable and 
unstable FKBP controls (thermal stability analysis from Table 4-1 is summarized in Figure 4-
10 B). Our thermal stability analysis showed that CLD1 has a higher level of stability than 
CLD2 or 3 and supported our hypothesis that CLD1 may be too stable to be effectively 
trafficked to the apicoplast in the absence of Shield1.   
 We also analyzed Shield1 sensitivity for each CLD (sensitivity analysis from Figure 
4-9 is summarized in Figure 4-10 C). This analysis showed that CLD1 is more sensitive to 
low concentrations of Shield1 than CLD 2 or 3. This is consistent with our thermal stability 
analysis because CLD1 is more stable than CLD2 or 3 and is likely more competent to bind 
Shield1 in vivo. Both CLD2 and 3 are less sensitive to low concentrations of Shield1 than 
CLD1. CLD2 has a limit of sensitivity around 25 nM, while CLD3 exhibited a partially 
secreted phenotype at 25 nM, and was fully secreted at 125 nM. The low sensitivity of CLD3 
to Shield1 combined with the slightly higher M1 values calculated for CLD3 in the presence 
of Shield1 (Figure 4-6 A) suggests that CLD3 may have a higher preference for trafficking to 
the apicoplast in the presence of Shield1 than CLD2. This difference in trafficking could be 
because of the higher net positive charge of CLD3 near the N-terminus - CLD3 has an 
increased net positive charge near the N-terminus of +3, while CLD2 only increases +2.  
Because CLD2 exhibited the most efficient trafficking to the apicoplast and secreted 
compartments, and is sensitive to concentrations of Shield1 well below the 1μM inhibitory 
concentration, CLD2 is likely to be the optimal domain for use in most validation studies. 
CLD3 appears to have a slight preference toward trafficking to the apicoplast in the presence 
of low levels of Shield1, and is less sensitive to Shield1 than CLD2. These features put 
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CLD3 in second place behind CLD2, in terms of its attractiveness for use in validations 
studies of the conditional localization system.  CLD1 has a leaky apicoplast trafficking 
phenotype and may be the least attractive candidate for some validation studies. CLD1 
however, could be an ideal domain to tag exogenously expressed proteins that are not 
normally active in the apicoplast. Whenever a protein is over expressed in the apicoplast 
there is a risk that it will not be tolerated at high levels in the organelle due to its activity. 
Tagging an exogenously expressed protein with CLD1 could prevent the toxic effects of 
overexpression because the protein is not trafficked to the apicoplast as efficiently as it 
would be with CLD2 or 3. This puts CLD1 in a unique position to be useful in some 
overexpression studies that traffic proteins to the apicoplast in P. falciparum.  
All of the features of CLD1, 2, and 3 evaluated in this chapter are useful to get an 
idea of how effectively each CLD traffics an ideal cargo protein, but they may vary in 
implementation studies with parasite proteins. Studies of FKBP fusion proteins have found 
that in general, C-terminal tags tend to destabilize FKBP8. The destabilizing effect of C-
terminal fusions on the CLD should have a positive effect on the domain’s ability to traffic 
to the apicoplast by allowing the domain to more closely mimic an unstructured apicoplast 
transit peptide. The positive effect of this destabilization is only useful however, if the CLD 
maintains the ability to bind Shield1 and change localization. The analysis of protein 
trafficking by CLD1, 2, and 3 described in this chapter are a useful guide for use of the 
domains but the size and stability of cargo proteins could cause trafficking dynamics of each 





Generation of plasmid constructs for expression of CLD1, 2, and 3 in E. coli 
Plasmids used for protein expression in E. coli were generated by PCR amplifying the 
human FKBP gene with Shield1 binding mutation 7 using forward primers that contain 
nucleotide changes to produce lysine mutations at residues 4, 6, or both (to generate CLD1, 
2 or 3 respectively). Fk4e6.EcoRI.LIC.for was used to generate CLD1, Fq4k6.EcoRI.LIC.for 
was used for CLD2, and Fkk.EcoRI.LIC.for was used for CLD3. One reverse primer 
(FKBP.P107L.HindIII.LIC.rev) was used to amplify the FKBP gene in all three reactions. 
PCR amplicons were then inserted into the pMALcHT 9 E. coli expression vector using ligase 
independent cloning with T4 DNA polymerase.  
 
Synchronization of parasites 
For experiments where parasites were synchronized, a homemade magnet with field 
strength of about 8,000 G was used to separate schizonts from mixed stage cultures. Briefly, 
a MACS LS Column (Miltenyi Biotec) was inserted into the homemade magnet and infected 
red blood cell culture was pipetted into the top of the column. When the column is attached 
to the magnet, schizonts stick to the magnetized beads while trophozoites and rings flow 
through. Schizonts were eluted from the column by taking it off of the magnet and running 
an additional 5 mL of media through the column.    
 
Statistical Analyses 
 In experiments where only two groups were compared, we conducted the Mann-
Whitney U test for analysis of non-normal, unpaired data sets. Comparisons of three or 
more groups were conducted using the Kruskal-Wallis one-way analysis of variance for non-
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normal, unpaired data sets. For both of these analyses, tests were considered statistically 
significant if the P-value was less than 0.05.  
 
 Immunofluorescence assays and live fluorescence imaging methods are the same as for 
Chapter 3.   
 Thermal Shift Assays and protein purification methods are the same as for chapter 3.  




Figure 4-1 Introduction to co-localization analysis 
A) Intensity scatter plot that represents an image of a cell with significant co-localization 
between ACP and SFG. The scatter plot shows a positive correlation between the two 
fluorochromes analyzed. 
B) Intensity scatter plot that represents an image of a cell that does not have significant co-
localization between ACP and SFG. The intensity scatter plot shows a lack of correlation 
between the two fluorochromes analyzed. 
C) The intensity scatter plot was generated from the images to its right. The FITC channel 
has a higher average intensity than the TRITC channel and so the points on the scatter plot 
are skewed towards the FITC axis. The M1 value for this image is higher than the PCC value 
because the M1 calculation does not take average intensity into account.  Microscopy images 
are 10μm long by 10μm wide. 
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Figure 4-2 Co-localization analyses for CLD1 
A) Immunofluorescence images of a transgenic parasite line that expresses CLD1 fused to 
SFG. The row labeled “-” shows a cell that has not been treated with Shield1 and the row 
labeled “+” shows a cell that was treated with 500 nM Shield1 for 72 hours before imaging. 
Images are 10 μm long by 10 μm wide. 
B) Mander’s Overlap Coefficients (M1) were calculated for immunofluorescence images 
similar to the ones shown in in part A. At least two independent immunofluorescence assays 
were done in the absence (left side graph) or presence (right side graph) of Shield1 and the 
M1 values were calculated for each cell.  
The Mann-Whitney U test was used to compare the M1 values from the two experiments 
done with 0 nM Shield1 and the Kruskal-Wallis one-way analysis of variance test was used to 
compare the three experiments done with 500 nM Shield1. Expt = Experiment 
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Figure 4-3 Co-localization analyses for CLD2 
A) Immunofluorescence images of a transgenic parasite line that expresses CLD2 fused to 
SFG. The row labeled “-” shows a cell that has not been treated with Shield1 and the row 
labeled “+” shows a cell that was treated with 500 nM Shield1 for 72 hours before imaging. 
Images are 10 μm long by 10 μm wide. 
B) Mander’s Overlap Coefficients (M1) were calculated for immunofluorescence images 
similar to the ones shown in in part A. At least two independent immunofluorescence assays 
were done in the absence (left side graph) or presence (right side graph) of Shield1 and the 
M1 values were calculated for each cell.  
The Mann-Whitney U test was used to compare the M1 values. 
Expt = Experiment  
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Figure 4-4 Co-localization analyses for CLD3 
A) Immunofluorescence images of a transgenic parasite line that expresses CLD3 fused to 
SFG. The row labeled “-” shows a cell that has not been treated with Shield1 and the row 
labeled “+” shows a cell that was treated with 500 nM Shield1 for 72 hours before imaging. 
Images are 10 μm long by 10 μm wide. 
B) Mander’s Overlap Coefficients (M1) were calculated for immunofluorescence images 
similar to the ones shown in in part A. At least two independent immunofluorescence assays 
were done in the absence (left side graph) or presence (right side graph) of Shield1 and the 
M1 values were calculated for each cell.  
The Mann-Whitney U test was used to compare the M1 values. 
Expt = Experiment 
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Figure 4-5 Co-localization analyses for protein trafficking controls 
A) Immunofluorescence images of transgenic parasites that expresses a constitutively 
apicoplast trafficked SFG protein (top row) or a constitutively secreted SFG protein (bottom 
row).  Images are 10 μm long by 10 μm wide. 
B) Mander’s Overlap Coefficients (M1) were calculated for immunofluorescence images 
similar to the ones shown in part A. Two independent immunofluorescence assays were 
done for each control line and the M1 values were calculated for each cell.  
The average M1 value for the apicoplast trafficking control is 0.821 and the average M1 value 
for the secreted trafficking control is 0.053.  
The Mann-Whitney U test was used to compare the M1 values. Expt = Experiment 
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Figure 4-6 Analysis of M1 values for CLD1, 2, and 3, compared to control trafficking 
constructs 
A) The M1 values calculated in the absence of Shield1 (- Shield1) for each CLD are 
compared to the apicoplast trafficking control (signal seq.ACP-transit pep.ACP-SFG) and the M1 
values calculated in the presence of Shield1 (+ Shield1) for each CLD are compared to the 
secreted trafficking control (signal seq.ACP-SFG). The M1 values for each CLD are compared 
to the appropriate control using the Mann-Whitney U test.  
B) Normalized co-localization values calculated for each CLD in the absence of Shield1 or 
after addition of 500 nM Shield1. The CLD data are normalized to the average of M1 values 
calculated for the trafficking controls presented in Figure 4-5. Normalized M1 values are 
compared using the Mann-Whitney U test.  
 
95 
Figure 4-7 Analysis of protein trafficking at each parasite developmental stage in the 
red blood cell 
The bar graph on the left compares apicoplast trafficking efficiency of each CLD at the ring, 
trophozoite, and schizont stage of development. There data are collected from cells that 
were not treated with Shield1 before imaging.  
The bar graph on the right compares secreted trafficking efficiency at the ring, trophozoite, 
and schizont stage of development. There data are collected from cells that were 
synchronized and then treated with 500 nM Shield1 for 72 hours before imaging. 
Both graphs show M1 values for CLD1, 2, and 3 that have been normalized to the average 
M1 values for trafficking controls presented in Figure 4-5. M1 values are compared for rings, 




Figure 4-8 Further analysis of the change in localization by CLD2 
The bar graph on the left shows the change in localization for CLD2 after 24 or 72 hours of 
treatment with 500 nM Shield1. The bar graph on the right shows the change in localization 
of CLD2 after 72 hours of treatment with 500 nM or 1uM Shield1. Cells were not 
synchronized for these experiments.  
For both experiments, the cells were stained with antibodies to track the location of SFG 
and ACP using the same methods described for Figure 4-3a. Co-localization analysis was 
done to calculate M1 values that were then normalized to the average M1 values of the 
trafficking controls presented in Figure 4-5. 
The Mann-Whitney U-test was used to compare the M1 values for each of the test conditions 




Table 4-1 Thermal stability analysis of CLD1, 2, and 3 
Thermal shift assays were done to determine the melting temperature of purified proteins. 
The change in melting temperature (ΔTm) is calculated by subtracting the Tm of CLD1, 2, 3 
or dFKBP from the Tm of sbFKBP. Melting temperatures are shown with standard 
deviations calculated from triplicate biological replicates. 







Figure 4-9 Sensitivity analysis of CLD1, 2, and 3 
Live fluorescence images of CLD1 (a), CLD2 (b), and CLD3 (c) with varying concentrations 
of Shield1 added to the culture media. Shield1 was added at appropriate concentrations for 











Figure 4-10 Summary of the analyses of protein trafficking by CLD1, 2, and 3 
presented in this chapter 
A) Apicoplast and secreted trafficking efficiency of each CLD is summarized. CLD2 and 3 
traffic to the apicoplast at similar levels while CLD1 has a leaky apicoplast trafficking 
phenotype. CLD1 and 2 are secreted at similar levels in the presence of Shield1 while CLD3 
is slightly less efficiently secreted in the presence of Shield1.  
B) Thermal stability analysis of each CLD is summarized compared to stable and unstable 
FKBP controls.  CLD2 and 3 are similarly destabilized while CLD1 is the most stable 
domain.  
C) Analysis of the sensitivity of each CLD to concentrations of Shield1 below 500 nM is 
summarized. CLD1 was sensitive to the lowest concentrations of Shield1 tested (5 nM). 
CLD2 is sensitive to slightly higher concentrations (25 nM) and CLD3 was the least sensitive 
to Shield1 (125 nM).    
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 To validate our conditional localization system we tested whether two of the CLDs 
analyzed in Chapter 4 could control the localization of a P. falciparum biotin ligase called 
Holocarboxylase Synthetase 1 (HCS1) without interfering with the function of the enzyme. 
 HCS1 is primarily localized in the cytosol but was shown to be the main ligase 
responsible for biotinylating the apicoplast targeted Acetyl-Coenzyme A Carboxylase (ACC) 
in liver stage Plasmodium parasites. Blood stage parasites also express HCS1 in the cytosol 
but at this stage the ligase is not active against the ACC. In this study we used the CLD to 
conditionally express HCS1 in the apicoplast to determine if localization of HCS1 controls 
its activity in blood stage parasites. In order to avoid potentially toxic effects of HCS1 
overexpression in the apicoplast we tagged HCS1 with CLD1, which has a leaky apicoplast 
trafficking phenotype. CLD1 was able to control the localization of HCS1 and HCS1 does 
not appear to be toxic in the apicoplast when trafficked by CLD1. We also showed that 
protein biotinylation in the apicoplast is controlled by altering the localization of HCS1 with 
Shield1. This experiment shows that CLD1 is able to control the localization of HCS1 
without affecting its biotin ligase activity.  
In our next experiment we investigated whether HCS1 activity in the apicoplast 
could activate downstream pathways, specifically the Type II Fatty Acid Synthesis (FAS II) 
pathway in the apicoplast. For this experiment we tagged HCS1 with CLD2, which traffics 
more efficiently to the apicoplast than CLD1. We confirmed that protein biotinylation in the 
apicoplast is also controlled in a ligand-dependent manner with the CLD2 tagged HCS1 
protein (CLD2-HCS1). To detect FAS II pathway products we radiolabeled newly 
synthesized fatty acids in parasites using [1-14C] -acetate and generated fatty acid methyl 
esters from parasite lysates that were analyzed by thin layer chromatography. We compared 
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fatty acid products produced by the CLD2-HCS1 expressing parasites in the absence and 
presence of Shield1 to products produced by the control parental parasite line and found no 
difference in fatty acids synthesized in any of the samples. This result suggests that HCS1 
activity may not be sufficient to activate the FASII pathway in blood stage parasites. 
Alternatively, [1-14C]-acetate may not be effectively absorbed into the apicoplast and this 
could also explain why we don’t see a difference in FAS II pathway activity.  
The validation experiments in this chapter demonstrate the full functionality of the 
conditional localization domain developed in this thesis. These CLDs may be used to tag 





We validated the conditional localization system by tagging an exogenous copy of the 
biotin ligase, Holocarboxylase Synthetase 1 (HCS1; PlasmoDB PF3D7_1026900). We chose 
this enzyme for our validation experiments because of previous studies in our lab that 
investigated the role of HCS1 in fatty acid metabolism. Fatty acids that are obtained from 
the host cell or synthesized de novo are important at all stages of the parasite life cycle to 
support the formation of membranes at morphologically and biochemically distinct stages1–3. 
P. falciparum has a Type II Fatty Acid Synthesis (FAS II) pathway located in the apicoplast 
and a fatty acid elongation pathway in the endoplasmic reticulum. Unlike Toxoplasma gondii – 
a related apicomplexan parasite – Plasmodium falciparum do not contain a Type I Fatty Acid 
Synthesis pathway in the cytosol4. (Figure 5-1 summarizes fatty acid synthesis and elongation 
pathways in P. falciparum) Previous studies from our group and others have shown that 
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HCS1 biotinylates the Acetyl-Coenzyme A Carboxylase (ACC). The ACC is a biotin 
dependent enzyme that performs the rate-limiting step in initiation of the FASII pathway. 
The ACC converts Acetyl-Coenzyme A (Acetyl-CoA) into malonyl-Coenzyme A (malonyl-
CoA), which is tethered to the Acyl Carrier Protein (ACP) and extended by the FASII 
elongation enzymes to generate long chain fatty acids. Our lab found that HCS1 activity is 
important for the initiation of fatty acid synthesis and normal liver stage parasite 
development but HCS1 is not active against the ACC in blood stage parasites5. Additionally, 
studies from other groups have shown that fatty acid synthesis is essential for parasite 
progression from liver to blood stage but it is not essential for continuation of the 
erythrocytic cycle3,6.  
Localization studies of HCS1 and the ACC showed that in liver and blood stage 
parasites HCS1 is primarily localized in the cytosol, while the ACC is trafficked to the 
apicoplast. HCS1 and the ACC are not expected to meet at any point during trafficking to 
their separate compartments in blood stage parasites and so we reasoned that some method 
of alternative trafficking must allow HCS1 to encounter and activate the ACC in the liver 
stage but not the blood stage. We therefore hypothesized that differential localization of 
HCS1 and the ACC during the blood stage of parasite development might control activity of 
HCS1 and possibly also activation of the downstream FASII pathway.  To investigate this 
hypothesis we tagged an exogenous copy of HCS1 with the CLD to allow us to express 
HCS1 in the apicoplast of blood stage parasites in a ligand dependent manner.  
We first investigated whether HCS1 activity in the apicoplast is dependent on the 
localization of the enzyme by using the CLD1 tag to conditionally express HCS1 in the 
apicoplast. We used anti-biotin antibodies to probe for biotinylation activity in the apicoplast 
of parasites expressing CLD1 tagged HCS1(CLD1-HCS1). We detected biotinylation of 
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apicoplast resident proteins in the absence of Shield1, and this activity was removed by 
adding Shield1 to cell culture media to change the localization of HCS1.  
In our next experiment we wanted to determine if activation of biotinylation in the 
apicoplast of blood stage parasites was sufficient to activate the FASII pathway. We 
generated an independent transgenic parasite line that expresses HCS1 fused to CLD2 
(CLD2-HCS1). To assay for FASII pathway activity we radiolabeled newly synthesized fatty 
acids in the CLD2-HCS1 expressing parasite line. We expected that because CLD2 traffics 
to the apicoplast more efficiently than CLD1, using the CLD2-HCS1 parasite line in these 
experiments would improve our chances of detecting FASII pathway products. We 
confirmed that CLD2 is able to control the localization and activity of HCS1 in blood stage 
parasites in a similar manner to CLD1 and proceeded to radiolabel (with [1-14C]-acetate) 
newly synthesized fatty acids in the presence and absence of Sheild1. We hypothesized that 
we might see different lengths of fatty acid products in samples that have not been treated 
with Shield1 if HCS1 activity in the apicoplast is sufficient to activate the FASII pathway. 
We did not however, detect any differences in fatty acids produced in parasites with HCS1 
active in the apicoplast (- Shield1) compared to those that did not have HCS activity in the 
apicoplast (+ Shield1) or the parental parasite line.  
These experiments show that controlling the localization of HCS1 with CLD1or 2 
can control the activity of this enzyme. We were not able to detect activation of the 
downstream FASII pathway in parasites with an active HCS1 in the apicoplast using 
radiolabeled acetate. This suggests that there may be other factors limiting the activation of 
the FASII pathway in blood stage parasites or that acetate does not enter the apicoplast. 
These studies however, have shown that the CLD can be used to control the location and 
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activity of a parasite enzyme. This provides proof of principle for future studies that will use 




Validation of CLD1 by tagging the biotin ligase HCS1 
Analysis of protein trafficking  
 Previous attempts in our lab to constitutively traffic HCS1 to the apicoplast from a 
high strength overexpression promoter (the P. falciparum Calmodulin promoter) failed and so 
we suspected that HCS1 might be toxic in the apicoplast compartment. For our experiments 
we switched to a lower strength promoter (the P. falciparum ribosomal L2 protein promoter) 
to express HCS1 fused to CLD1. We chose CLD1 because it has a leaky apicoplast 
trafficking phenotype and we reasoned that expressing HCS1 from a lower strength 
promoter, trafficked by a low efficiency CLD, could allow this ligase that is not normally 
expressed in the apicoplast compartment to be better tolerated by the cell.  
 We analyzed protein trafficking in live fluorescence images of cells expressing CLD1 
tagged HCS1 (CLD1-HCS1; protein expression construct is diagramed in the top part of 
Figure 5-2). In the absence of Shield1 (“- Shield1” rows in Figure 5-2) we observed a 
trafficking pattern that is characteristic of apicoplast localization at each stage in parasite 
development in the red blood cell. In the ring stage the apicoplast is a single dot-like 
organelle that is located on the edge of the cell, in the trophozoite stage the apicoplast 
branches out, and in the schizont stage the apicoplast divides into multiple daughter 
organelles that get packaged into each new merozoite. When we added Shield1 to cell culture 
media (“+ Shield1 rows in Figure 5-2), the CLD1-HCS1 protein changes localization to 
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become secreted from the cell at all three stages of parasite development. The secreted 
protein accumulates in the parasitophorous vacuole space that separates the parasite from 
the red blood cell cytosol. In later stages (trophozoites and schizonts) some of the protein 
also appears to be taken back into the cell and accumulates in the digestive vacuole. This 
trafficking pattern of accumulation in the digestive vacuole as well as the parasitophorous 
vacuole after the addition of Shield1 to cell culture media was also observed for the CLD1 
test construct described in Chapter 3 (Figure 3-4).  
We confirmed the trafficking patterns observed in Figure 5-2 by staining cells in 
immunofluorescence assays with antibodies to track the location of the CLD trafficked 
HCS1-SFG protein and the apicoplast marker ACP (Figure 5-3 A). The top row in Figure 5-
3 A shows cells that have not been treated with Shield1; under this condition the SFG 
protein partially co-localizes with ACP. Some of the HCS1-SFG protein also accumulates in 
the parasitophorous vacuole space. This trafficking pattern is consistent with the leaky 
apicoplast trafficking phenotype previously described for CLD1. When we added 500 nM 
Shield1 to cell culture media for 72 hours, we no longer observed significant co-localization 
between the ACP and SFG proteins (Figure 5-3 A bottom row).  After Shield1 is added to 
cell culture media the SFG signal accumulates outside the cell in the parasitophorous vacuole 
space. Some protein is also observed inside the cell but not co-localized with ACP and is 
presumably en route to be secreted from the cell. 
To quantitatively analyze the level of co-localization between SFG and ACP in 
immunofluorescence images, we calculated the Mander’s Overlap Coefficient (M1 is 
described in detail in Chapter 4) to determine the fraction of SFG intensities that overlap 
with ACP in the presence or absence of Shield1 (Figure 5-3 B). In the absence of Shield1 we 
observed partial co-localization between SFG and ACP in immunofluorescence images 
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(Figure 5-3 A) and consistent with this observation, we also calculated higher M1 values for 
these cells compared to cells that were treated with Shield1 (Figure 5-3 B). The M1 values 
calculated from immunofluorescence images of cells treated with Shield1 declined 
significantly (Figure 5-3 B), indicating that the HCS1-SFG protein is secreted from the cell 
and no longer traffics to the apicoplast. These analyses of protein trafficking in live (Figure 
5-2) and fixed (Figure 5-3) cell samples show that CLD1 is able to control the localization of 
the HCS1-SFG cargo protein.  
 
Analysis of biotinylation activity  
 In our next experiment we investigated whether localization of HCS1 controls its 
activity. HCS1 has only one predicted target protein in the parasite, which is the ACC. The 
ACC is an apicoplast resident protein and so we expected to observe biotinylation activity 
when HCS1 is trafficked to the apicoplast (- Shield1) and no activity in the apicoplast when 
HCS1 is removed (+ Shield1). We assayed for biotinylation activity in the apicoplast by 
staining cells in immunofluorescence assays with antibodies against biotin and the apicoplast 
marker ACP. The top row in Figure 5-4 shows that when HCS1 is trafficked to the 
apicoplast (- Shield1) we detect biotinylation activity that co-localizes with the apicoplast 
marker protein (ACP). This activity is absent when we change the localization of HCS1 by 
adding Shield1 to cell culture media. In the bottom 2 rows of Figure 5-4, cells have been 
treated with 500 nM Shield1 for 72 hours before immunofluorescence analysis. We did not 
detect biotinylation in the apicoplast of samples treated with Shield1. The image in the third 
row in Figure 5-4 is the same cell in the second row but the FITC channel has been 
brightened to show that there is no detectable enhancement of biotinylation signal above 
background in the apicoplast organelle.  
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This analysis shows that altering the localization of HCS1 can control the activity of 
the enzyme. When we traffic HCS1 to the apicoplast using CLD1 it is able to biotinylate an 
apicoplast resident protein that is presumably the ACC. In our next study we investigated 
whether HCS1 activity in the apicoplast is sufficient to activate the downstream FASII 
pathway. We reasoned that to improve our chances of detecting FASII pathway activity in 
parasites we should tag HCS1 with a CLD that traffics more efficiently to the apicoplast 
organelle. For this study we generated a second parasite line that expresses an exogenous 
copy of HCS1 tagged with CLD2 instead of CLD1.    
 
Validation of CLD2 by tagging the biotin ligase HCS1 
Analysis of protein trafficking  
 We generated a transgenic parasite line that expresses the HCS1 biotin ligase fused to 
CLD2 (CLD2-HCS1; protein expression construct is diagramed in top part of Figure 5-5) 
and analyzed protein trafficking in live fluorescence images of this cell line. In the absence of 
Shield1 (“- Shield1” rows in Figure 5-5) we observed a trafficking pattern that is consistent 
with apicoplast trafficking at all three stages of parasite development in the red blood cell 
(typical apicoplast trafficking characteristics were reviewed in the previous section and 
described in detail in Chapter 1). When Shield1 was added to cell culture media (“+ Shield1” 
rows in Figure 5-5) we observed a change in SFG localization as the HCS1-SFG protein is 
secreted from the cell and accumulates in the parasitophorous vacuole space. We also 
observed some protein that is taken back into the cell’s digestive vacuole after secretion, 
which is consistent with our previous analysis of CLD2 trafficking in the presence of Shield1 
described in Chapter 3 (Figure 3-5).  
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 We confirmed the trafficking patterns observed in live fluorescence images of the 
CLD2-HCS1 parasite line by staining cells in immunofluorescence assays. We analyzed 
localization of the CLD2 trafficked HCS1-SFG and the apicoplast marker ACP. Figure 5-6 
A shows representative images from our analysis of cells left untreated (“- Shield1”) or 
treated with 500 nM Shield1 for 72 hours before analysis (“+ Shield1”). In the absence of 
Shield1 we observed co-localization between ACP and SFG (Figure 5-6 A top row). When 
we added Shield1 to cell culture media we no longer detect significant co-localization 
between ACP and SFG and the SFG protein is accumulated in the parasitophorous vacuole 
space (Figure 5-6 A bottom row).  
We quantified the level of co-localization between ACP and SFG by calculating M1 
values (M1 is a colocalization statistic that was described in detail in Chapter 4) for each cell 
analyzed in immunofluorescence assays done in the absence or presence of Shield1. The bar 
graph in Figure 5-6 B shows that in the absence of Shield1 the M1 values are higher, 
indicating that CLD2 traffics the HCS1-SFG protein to the apicoplast. When we treated cells 
with Shield1 we observed a decline in co-localization between ACP and SFG as the CLD2 
tag causes HCS1-SFG to be secreted from the cell. The average M1 value calculated for the 
CLD2-HCS1 line in the absence of Shield1 is higher than the average M1 value calculated for 
the CLD1-HCS1 line. This confirms that CLD2 traffics HCS1 to the apicoplast more 
efficiently than CLD1.  
 
Analysis of biotinylation activity 
 In our next experiment we confirmed that controlling the localization of HCS1 with 
CLD2 controls the activity of the ligase – as was observed with CLD1. We assayed for 
biotinylation activity in the apicoplast by staining cells in immunofluorescence assays with a 
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streptavidin-FITC molecule and antibodies against the apicoplast marker ACP. Figure 5-7 
shows that when HCS1 is trafficked to the apicoplast (“- Shield1”, top row) we can detect 
biotinylation activity that co-localizes with the apicoplast. This is presumably biotinylation of 
the ACC, since the ACC is the only known target of HCS1 in the apicoplast. When we 
added Shield1 to cell culture media to change the localization of HCS1 (Figure 5-7 bottom 
two rows), the biotinylation activity is removed from the apicoplast organelle. The third row 
in Figure 5-7 is the same cell as in the second row, except the FITC channel has been 
brightened to show that there is no detectable enhancement of biotinylation signal in the 
apicoplast.  
Our analysis of biotinylation activity in the CLD1-HCS1 and CLD2-HCS1 
expressing parasite lines (Figure 5-4 and 5-7) shows that altering the localization of HCS1 
using Shield1 can control HCS1 activity in the apicoplast. Since CLD2 traffics HCS1 to the 
apicoplast more efficiently than CLD1 and does not interfere with the biotin ligase activity 
of HCS1, we proceeded with studies to investigate whether the downstream FASII pathway 
is activated when an active HCS1 enzyme is trafficked to the apicoplast by CLD2.  
 
Analysis of FASII pathway activity  
 We assayed for FASII pathway activity in the CLD2-HCS1 parasite line by labeling 
newly synthesized fatty acids with [1-14C]-acetate. We hypothesized that the labeled acetate 
could be converted to acetyl-CoA by the parasites and serve as a substrate for the FASII 
pathway in the apicoplast (Figure 5-8 shows a model of how [1-14C]-acetate might label 
FASII pathway products in the parasite). After 24 hours of labeling with [1-14C]-acetate we 
lysed the parasites, extracted fatty acids, and generated fatty acid methyl esters (FAMEs) to 
resolve on a high performance thin layer chromatography (HPTLC) silica gel. The gel was 
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exposed to an imaging plate and then imaged on a phosphoimager to detect radiolabeled 
fatty acid species.  
For this experiment we labeled the CLD2-HCS1 parasite line in the presence  and 
absence of Shield1 and also a control parental parasite line (dd2attB) that does not express 
an exogenous copy of HCS1. Figure 5-9 (left side) shows the FAME species detected on the 
imaging plate after one week of exposure to the HPTLC gel. The same FAME species are 
detected in the dd2attB control parasites as in the CLD2-HCS1 parasite lines with 0 or 500 
nM Shield1 added to cell culture media. The difference in intensity of the FAME species 
generated in each sample is likely because of the slightly different final parasitemias reached 
by each culture after three days of incubation in the presence or absence of Shield1 and then 
24 hours of radiolabeling.  
Previous studies have shown that in parasites that lack a critical enzyme for FASII 
pathway activity – a FabI knock out parasite line – C16 and C18 are still synthesized, 
presumably through the fatty acid elongation pathway in the endoplasmic reticulum3. All of 
the FAME species detected in the CLD2-HCS1 samples are likely synthesized by the fatty 
acid elongation pathway since they are also present in the parental parasite strain sample 
which does not have an active FASII pathway. Flux though the fatty acid elongation 
pathway could mask low levels of FASII pathway activity in the ‘- Shield1’ CLD2-HCS1 
sample. To address this concern we exposed the HPTLC gel to the imaging plate for an 
additional two and a half months (Figure 5-9 right side) to try to detect low levels of FASII 
pathway products. We did not however see any difference in fatty acid products produced 
after this longer exposure compared to the one-week exposure.    
 
CONCLUSIONS AND DISCUSSION 
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 Previous studies from our lab have shown that HCS1 is active in the apicoplast of 
liver stage parasites5. HCS1 biotinylates the ACC which then generates substrates for fatty 
acid synthesis that are essential for normal liver stage parasite development 3,5–7. In blood 
stage parasites HCS1 is not active and studies have shown that fatty acid synthesis is 
dispensable at this stage of parasite development3,5. Localization studies of HCS1 and its 
substrate, found that in both liver and blood stage parasites the ACC is trafficked to the 
apicoplast while HCS1 is primarily cytosolic. We hypothesized that differential HCS1 
localization in blood stage parasites might control its activity. We reasoned that since HCS1 
does not encounter the ACC in blood stage parasites it is inhibited form activating the ACC 
and initiating FASII pathway activity. We tagged HCS1 with the CLD to test if changing the 
localization of HCS1 so that it encounters the ACC in blood stage parasites is sufficient to 
allow HCS1 to biotinylate the ACC and activate fatty acid synthesis at this stage.      
Both CLD1 and CLD2 were able to control the localization of HCS1 (Figures 5-2, 5-
3, 5-5, and 5-6) and independently confirm that altering the localization of HCS1 can control 
its activity in blood stage P. falciparum. HCS1 is active against an apicoplast-targeted substrate 
that is presumably the ACC, and this activity is removed when HCS1 is removed from the 
apicoplast (Figures 5-4 and 5-7). We tested whether HCS1 activity was sufficient to activate 
the FASII pathway by radiolabeling fatty acids in parasites that express HCS1 in the 
apicoplast (- Shield1) or secreted compartments (+ Shield1). We found no difference in fatty 
acid species produced in parasites that had an active HCS1 enzyme in the apicoplast 
compared to those in which the enzyme was secreted (Figure 5-9). This result could indicate 
that [1-14C]-acetate is not effectively taken into the apicoplast. Studies in trypanosomes – 
another protozoan parasite – found that [1-14C]-acetate had a lower capacity for cellular 
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uptake compared to pyruvate or glucose8. Future experiment with this parasite line could 
attempt to label fatty acids with glucose instead of acetate. Figure 5-8 shows how glucose 
could also be used to label FASII pathway products in P. falciparum. Briefly, in the cytosol 
glucose is converted into phosphoenolpyruvate (PEP), which can be taken into the 
apicoplast via a membrane transporter (the PEP/phosphate translocator; PPT)9. PEP is 
converted to pyruvate, which is used to generate the substrate for the ACC, acetyl-CoA7,10.   
A third experiment that could detect FASII pathway activity and does not rely on 
metabolic labeling is to pull down the Acyl-Carrier Protein (ACP). ACP anchors the growing 
fatty acid chain during the elongation cycle of fatty acid synthesis7. We expect that if we pull 
down the ACP in parasites that have HCS1 expressed in the apicoplast – and the FASII 
pathway is active  – we should be able to detect fatty acids attached to the protein using mass 
spectrometry. In parasites that have HCS1 secreted from the cell (+ Shield1) or the parental 
parasite strain, we expect that we would not detect fatty acids attached to ACP since the 
FASII pathway is not thought to be active in blood stage parasites when HCS1 is not 
trafficked to the apicoplast.   
An alternative explanation for the lack of FASII pathway activity detected in Figure 
5-9 is that HCS1 activity alone is not sufficient to activate the downstream FASII pathway. 
Several other enzymes and substrates are required for activation of the FASII elongation 
cycle and we cannot rule out the possibility that there are other rate limiting steps that 
prevent FASII from being activated in blood stage parasites. Although the question of 
whether HCS1 activity in the apicoplast is sufficient to activate the FASII pathway could be 
further investigated in future experiments, this study has met the goal of validating the 
conditional localization system developed in this thesis. In this chapter we showed that the 
CLD could be used to control the activity of a parasite protein (HCS1) without interfering 
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with the function of the enzyme (biotinylation activity). This study sets the stage for future 
experiments in our lab that will use the CLD to investigate the function of other parasite 




Generation of plasmid constructs for parasite expression of CLD1-HCS1 and CLD2-
HCS1 
 The HCS1 gene was amplified from plasmid DNA 5 using BsrG1.HCS10.for and 
BsiWI.HCS10.rev (Table 5-1) and digested with BsiWI and BsrGI. pRL2 parasite expression 
vectors described in Chapter 3 to express CLD1 and CLD2 were then also digested with 
BsiWI. The HCS1 gene was ligated into the CLD1 and CLD2 vectors for parasite expression 
using Quick Ligase (New England BioLabs). DNA sequences were confirmed by sequencing 
after insertion.  
 
Anti-biotin and Streptavidin-FITC Immunofluorescence Assays 
Microscope slides were set up for immunofluorescence assays by drawing wells on 
the slide with a Super Pap Pen Liquid Blocker (Ted Pella, inc.). A .01 % poly-L-Lysine 
solution (Sigma-Aldrich) in water was added to each well and allowed to dry for at least 30 
minutes. 300μl of parasite culture was then spun down and resuspended in an equal volume 
of fixative (4 % paraformaldehyde and .0075 % glutaraldehyde in PBS). Cells were added to 
each well on the slide and then incubated for 30 minutes at room temperature. After 
incubation, fixed cells were permeabilized by incubation in 1 % Triton for ten minutes. The 
samples were then reduced by incubation in 100 μg/ml NaBH4 for 10 minutes. Next the cells 
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were incubated in blocking solution (3 % BSA in PBS) for two hours. Before applying 
primary antibodies cells were washed in PBS and then incubated with appropriate antibodies 
at 4°C. For anti-biotin IFA experiments, cells were left in primary antibodies over the 
weekend and if streptavidin-FITC was used the cells were left in the primary antibody 
overnight.  [Rabbit polyclonal αACP 1:500, raised against the P. falciparum antigen; 
monoclonal mouse αBiotin 1:50(Sigma)]. Cells were then washed three times in PBS and 
then once in 3 % BSA. Appropriate secondary antibodies  [goat αrabbit AlexaFluor 594 
1:1000 (Life Technologies); goat αmouse AlexaFluor 488 1:1000 (Life Technologies)] or 
streptavidin-FITC reagent (1:50) was added to cells and incubated for 2 hours in the dark at 
room temperature. Finally cells were washed in PBS three times and sealed with ProLong 
Gold antifade reagent with DAPI (Life Technologies) under a coverslip sealed with nail 
polish. Slides were allowed to sit overnight at room temperature before imaging analysis on 
the Zeiss AxioImager M2 microscope.  
 
[1-14C]-acetate labeling and extraction/generation of FAMEs 
 After 3 days of culture in 0 nM or 500 nM Shield1, parasites were synchronized using 
a magnetic column (as previously described in Chapter 4) and 50 μCi of [1-14C]-acetate was 
added to 5mL of cell culture media. Parasite were allowed to grow in the presence of 
radiolabeled acetate for 24 hours before cell pellets were collected, snap frozen in liquid 
nitrogen and stored in the -80 °C freezer overnight.  
 The next day the cells were saponin lysed in 0.05 % saponin and washed in 
Phosphate Buffered Saline twice. Parasite pellets were then resuspended in 400μl 5M 
KOH/10 % Methanol and heated at 80 °C for one hour to extract free fatty acids. 400 μL of 
5M H2SO4 was added to the solution and fatty acids were extracted using 1 mL of Hexane. 
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Fatty acids were evaporated under Nitrogen gas and then dissolved in 750 μl 1.25 M 
methanolic HCl and heated for 1 hour at 80 °C. 750 μl 0.15 M NaCl was added to the 
solution and FAMEs were extracted using hexane and evaporated under nitrogen gas again. 
The FAMEs were finally resuspended in 50 μl chloroform and resolved on a HPTLC‐RP18 
reversed phase unibond octadecyl modified silica gel using 5:15:1 CHCl3: MeOH : H2O. 
Radiolabeled FAME product were exposed to an imaging plate for 1 week or 2.5 months 
and then imaged using a phosphoimager.  
 All other immunofluorescence assays and live fluorescence imaging methods are the 
same as for Chapter 3.   
 Parasite culture methods are the same as for Chapter 2. 











Figure 5-1 Fatty Acid Metabolism in P. falciparum 
P. falciparum has a fatty acid elongation pathway in the endoplasmic reticulum that can 
elongate C16 to C18 in blood stage parasites11. P. falciparum also has a Type II Fatty Acid 
Synthesis (FASII) pathway in the apicoplast that is required for liver stage parasite 
development but not the erythrocytic cycle3,6. Glucose metabolism in the cytosol produces 
phosphoenolpyruvate (PEP), which is taken into the apicoplast by the PEP/phosphate 
translocator (PPT). PEP is converted to pyruvate (Pyr), which is used to generate acetyl-
Coenzyme A (Ac-CoA). The Acetyl-CoA Carboxylase (ACC) is a biotin dependent enzyme 
that converts Ac-CoA into malonyl-CoA, which is attached to the holo-Acyl Carrier Protein 
and modified by FASII pathway elongation enzymes to generate long chain fatty acids. The 
ACC is biotinylated by a biotin ligase that is primarily localized in the cytosol of blood stage 
parasites called the Holocarboxylase Synthetase 1 (HCS1).    
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Figure 5-2 Analysis of protein trafficking by CLD1-HCS1  
The diagram on the top shows the protein expression construct for CLD1-HCS1.  
Signal Seq.ACP = signal sequence from the Acyl Carrier Protein 
CLD1 = conditional localization domain 1 (FKBPQ4K, F36V)  
HCS1 = holocarboxylase synthetase 1 
 SFG = super folder green 
 
The cell images are live fluorescence images of transgenic parasites that express CLD1-
HCS1. The rows labeled “-” are cells that have not been treated with Shield1 and rows 
labeled “+” are cells that have been treated with 500 nM Shield1 for 24 hours. The 
development stage of each parasite is estimated based on the number of nuclei and the size 
of the parasite relative to the red blood cell.  
Images are 10μm long by 10μm wide. 
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Figure 5-3 Co-localization analyses for CLD1-HCS1 
A) Immunofluorescence images of a transgenic parasite line that expresses CLD1 fused to 
HCS1-SFG. The row labeled “-” shows a cell that has not been treated with Shield1 and the 
row labeled “+” shows a cell that was treated with 500 nM Shield1 for 72 hours before 
imaging. Images are 10μm long by 10μm wide. 
B) Mander’s Overlap Coefficients (M1) were calculated for immunofluorescence images 
similar to the ones shown in in part A. M1 values were calculated for each cell and all values 
were normalized to the average of the trafficking controls presented in Chapter 4 (Figure 4-
5).  
The Mann-Whitney U test was used to compare the M1 values from the – and + Shield1 
groups.   
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Figure 5-4 Analysis of biotinylation activity in the CLD1-HCS1 expressing parasite 
line 
Immunofluorescence images of cells with no Shield1 added to culture (- Shield1) or 500 nM 
Shield1 added for 72hours (+ Shield1). The bottom row shows the same image in the second 





Figure 5-5 Analysis of protein trafficking by CLD2-HCS1 
The diagram on the top shows the protein expression construct for CLD2-HCS1.  
Signal Seq.ACP = signal sequence from the Acyl Carrier Protein 
CLD2 = conditional localization domain 2 (FKBPE6K, F36V)  
HCS1 = holocarboxylase synthetase 1 
 SFG = super folder green 
 
The cell images are live fluorescence images of transgenic parasites that express CLD2-
HCS1. The rows labeled “-” are cells that have not been treated with Shield1 and rows 
labeled “+” are cells that have been treated with 500 nM Shield1 for 24 hours. The 
development stage of each parasite is estimated based on the number of nuclei and the size 
of the parasite relative to the red blood cell. Images are 10μm long by 10μm wide. 
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Figure 5-6 Co-localization analyses for CLD2-HCS1 
A) Immunofluorescence images of a transgenic parasite line that expresses CLD2 fused to 
HCS1-SFG. The row labeled “-” shows a cell that has not been treated with Shield1 and the 
row labeled “+” shows a cell that was treated with 500 nM Shield1 for 72 hours before 
imaging. Images are 10 μm long by 10 μm wide. 
B) Mander’s Overlap Coefficients (M1) were calculated for immunofluorescence images 
similar to the ones shown in in part A. M1 values were calculated for each cell and all values 
were normalized to the average of the trafficking controls presented in Chapter 4 (Figure 4-
5).  
The Mann-Whitney U test was used to compare the M1 values from the – and + Shield1 




Figure 5-7 Analysis of biotinylation activity in the CLD2-HCS1 expressing parasite 
line 
Immunofluorescence images of cells with no Shield1 added to culture (- Shield1) or 500 nM 
Shield1 added for 72hours (+ Shield1). The bottom row shows the same image in the second 
row with brightness enhanced in FITC channel. Images are 10μm long by 10μm wide. 




Figure 5-8 Model of how [1-14C]-acetate could be used to label FASII pathway 
products 
[1-14C]-acetate is taken into the infected red blood cell and converted into Acetyl-Coenzyme 
A (Ac-CoA) by the Ac-CoA Synthetase (ACS) in the cytosol. This molecule must then be 
imported into the apicoplast into order to be used as a substrate for the FASII pathway.   





Figure 5-9 Analysis of FASII pathway activity in the CLD2-HCS1 parasite line  
After treatment with 0 nM or 500 nM Shield1 for 72 hours parasites were synchronized and 
then radiolabeled with [1-14C] acetate for 24 hours to label newly synthesized fatty acids. 
Fatty acids were extracted to generate fatty acid methyl esters (FAMEs) and resolved on an 
HPTLC silica gel. The gel was exposed to an imaging plate for one week (left) or 2.5 months 
(right).  
 CLD2-HCS1 samples treated with 0 nM Shield1 have an active HCS1 enzyme 
expressed in the apicoplast.  
 CLD2-HCS1 samples treated with 500 nM Shield1 do not have an active HCS1 
enzyme in the apicoplast 
 The parental dd2attB strain does not overexpress HCS1 and is not expected to have 
an active FASII pathway since the FASII pathway is dispensable in blood stage 
parasites.  
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Development and Future Studies of the Conditional Localization Domain 
 This thesis describes the design, characterization, and validation of a novel molecular 
tool that can be used to control the localization of apicoplast targeted proteins. We designed 
a conditional localization domain (CLD) that can be added as an amino-terminal tag to a 
protein of interest and to control its localization. The CLD mimics the features of natural P. 
falciparum transit peptides and is destabilized without an interacting ligand, which allows it to 
traffic to the apicoplast. When a ligand is added to cell culture media, it stabilizes the 
structure of the CLD and causes the domain to be secreted from the cell.  
We tested Dihydrofolate Reductase (DHFR) and FK-506 Binding Protein (FKBP) as 
candidate CLDs in Chapters 2 and 3 respectively. Our DHFR variants were not suitable 
CLDs because they did not traffic to the apicoplast. There are several reasons why DHFR 
may have performed poorly as a CLD. Our analysis suggests that DHFR’s ability to bind 
multiple ligands, its enzymatic activity, or its complex amino-terminal structure may have 
contributed to its inability to traffic to the apicoplast. We then moved on to design our next 
candidate CLDs, which were ultimately successful, from FKBP.  FKBP has been used as a 
molecular tool in many eukaryotic cell systems including multiple tools designed for use in P. 
falciparum and has been engineered to bind a synthetic ligand (Shield1) with higher affinity 
than endogenous ligands1–4. We designed three CLDs – CLD1, CLD2, and CLD3 – that are 
able to traffic to the apicoplast and secreted compartment in a ligand dependent manner. In 
Chapter 4 we conducted an analysis of trafficking dynamics, structural stability, and 
sensitivity of each of the CLDs (A summary of these analyses is diagramed in Figure 4-10). 
Most notably, we found that CLD1 has a leaky apicoplast trafficking phenotype that is linked 
to its higher protein stability compared to CLD2 or 3. We also showed that CLD2 has the 
most optimal trafficking efficiency to the apicoplast and secreted compartments.  
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In the final portion of this thesis we validated the conditional localization system by 
tagging a parasite biotin ligase (Holocarboxylase Synthetase 1; HCS1) with CLD1 and then 
CLD2. We showed that altering the localization of the HCS1 enzyme controls HCS1 activity 
in the apicoplast. This study proved that the CLD can be used to control the localization of 
a parasite enzyme without interfering with the function of the protein and demonstrates the 
full functionality of the CLD tool.  
 There are some characteristics of the CLDs that could be further modified in future 
studies to improve the domains. One feature that could be further studied is the CLD 
cleavage site. Natural transit peptides are cleaved after they are imported into the apicoplast 
lumen by a metalloprotease called the Stromal Processing Peptidase (SPP; 
PF3D7_1440200.1)5. The signal for transit peptide recognition and cleavage by PfSPP is 
currently unknown. Studies of similar transit peptide cleavage enzymes in chloroplasts 
however, have identified two short consensus sequences (between four and six amino acids 
long) that appear to be involved in recognition of some transit peptides in plants 6. While no 
such consensus sequence has been identified for P. falciparum transit peptides, the exact site 
of transit peptide cleavage for the apicoplast marker Acyl-Carrier Protein (ACP) has been 
mapped (see ACP cleavage site in Figure 6-1 A)5.  
Since we do not know what the exact sequence recognition signal is for the PfSPP, 
we decided to insert the three amino acid residues around the ACP cleavage site after the 
CLD sequence (see CLD cleavage site in Figure 6-1 B) as an artificial transit peptide cleavage 
site that would hopefully allow the CLD to be cleaved from the mature protein after import 
into the apicoplast. Preliminary studies of the CLD cleavage site showed that the CLDs are 
cleaved from SFG when the domain traffics to the apicoplast (- Shield1) and also when the 
domain traffics to the parasitophorous vacuole (+ Shield1). This suggests that the PfSPP in 
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the apicoplast is not the only protease capable of cleaving the artificial cleavage site we 
inserted after the CLD. Additionally, studies from other groups have shown that proteases 
are among the most abundant proteins in the parasitophorous vacuole7. It is plausible that 
one or more of the proteases present in the parasitophorous vacuole space is able to cleave 
the artificial transit peptide cleavage site that we inserted after the CLD. Further studies to 
improve the CLD could test longer sequences for the CLD cleavage site to generate a cut 
site for the CLD that is exclusively recognized by the SPP in the apicoplast. This would 
allow future studies that implement the CLD to track protein localization by analyzing the 
size of the target protein on a western blot in addition to visualizing localization using 
microscopy. 
 
Implementation of the Conditional Localization Domain in Future Studies 
 There are over 500 proteins that are predicted to be targeted to the apicoplast in P. 
falciparum8. Many of these proteins participate in biochemical pathways that perform essential 
functions in the apicoplast such as the Type II fatty acid synthesis pathway and the 
isoprenoid precursor synthesis pathway. Other proteins are involved in maintenance of the 
apicoplast genome, organelle morphology, or protein import to the apicoplast. Any of these 
proteins may be of interest in future studies that could use the CLD to probe their function 
or viability as a drug target.  
There are however, some limitations on the use of the CLD, in particular for tagging 
proteins that are trafficked to the apicoplast membrane. Four membranes surround the 
apicoplast and only a few studies have characterized proteins that are trafficked to these 
membranes9,10. These studies have shown that some proteins that traffic to the apicoplast 
membrane do not contain a canonical bipartite apicoplast trafficking motif. The molecular 
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mechanism for apicoplast targeting without a transit peptide motif is still unknown and it is 
difficult to predict how adding a CLD to the amino-terminus a membrane protein that does 
not contain a transit peptide would affect its trafficking. Use of the CLD is therefore likely 
limited to proteins that are soluble and trafficked to the apicoplast lumen by a canonical 
signal sequence and transit peptide motif. 
The CLD could also be used to tag soluble proteins in the parasitophorous vacuole. 
A proteomic study of the parasitophorous vacuole revealed that proteases and chaperones 
are the most abundant proteins in the parasitophorous vacuole space7. Some of these 
proteases are likely to be involved in release of mature merozoites from the red blood cell. 
Future studies could use the CLD to mislocalize proteases in the parasitophorous vacuole 
and determine which enzymes are important for parasite egress. This type of study can only 
be successful however if the protease is not toxic when trafficked to the apicoplast 
compartment.  
Currently our lab is in the process of tagging several proteins with the CLD at their 
endogenous locus. Our goal is to use the CLD to mislocalize a protein that is important for 
apicoplast maintenance and then follow the metabolic and morphological changes that occur 
in the cell, as the protein is mislocalized (by adding Shield1) and the apicoplast is lost. We are 
also interested in disseminating the conditional localization domain to other labs. Some labs 
have expressed interest in applying the CLD to control apicoplast-targeted proteins in 
Toxoplasma gondii (a related apicomplexan parasite). This may be feasible since T. gondii has 
similar amino-terminal targeting motif requirements for trafficking to the apicoplast as P. 
falciparum11,12. It is not clear however whether the structural features of T. gondii transit 
peptides are similar to those of P. falciparum and this would be a key determinant for the 
successful use of the CLD in other plastid containing organisms.  
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Figure 6-1 Stromal Processing Peptidase cleavage sites for ACP and the CLD 
A) The amino-terminal sequence of the Acyl-Carrier Protein (ACP) is shown5. The arrow 
indicates where the P. falciparum Stromal Processing Peptidase (PfSPP) cleaves this sequence 
as the protein is imported into the apicoplast lumen.  
B) We inserted the six amino acid sequence around the transit peptide cleavage site of ACP 
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 The study described in this appendix was a part of a larger line of research in our lab 
that interrogates the role of lipoate in the parasite mitochondrion. Lipoate is an enzyme 
cofactor that is scavenged by the parasite for use in the mitochondrion and is essential for 
blood stage parasite development 1. Lipoate is attached to three parasite proteins in the 
mitochondrion that each function as a part of larger multi-enzyme complexes2. One of these 
lipoylated proteins is the H-protein, which is a part of the glycine cleavage complex of 
enzymes. And the other two lipoylated proteins are the mitochondrial pyruvate 
dehydrogenase (mPDH) and the α-ketoglutarate dehydrogenase (KDH). Both the mPDH 
and KDH are members of multi-enzyme complexes that generate products used by the 
tricarboxylic acid (TCA) cycle2. 
 A former student in our lab investigated how lipoate is attached to each of its target 
proteins in the mitochondrion. There are two predicted lipoate ligases in P. falciparum called 
Lipoate Ligase 1 and 2 (Lipl1 and Lipl2). Studies of these two enzymes showed that Lipl1 is 
able to lipoylate the H-protein independent of Lipl2 activity. Lipl2 however, does not appear 
to have the expected lipoate ligase activity. Lipl2 instead acts as a transferase that takes 
activated lipoate from Lipl1 and attaches it to the target proteins: KDH and mPDH3.  
Previous studies form other groups have localized the Lipl1 and Lipl2 proteins to 
different compartments in the cell. Using episomal over-expression methods, Lipl1 was 
localized exclusively to the mitochondrion while Lipl2 was localized to both the 
mitochondrion and the apicoplast4,5. Given our studies showing that Lipl2 is not a ligase and 
requires Lipl1 for activity, it is unclear what the function of Lipl2 would be in the apicoplast 
without Lipl1. I began this study to try to confirm the reported dual localization of Lipl2 
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with an improved overexpression technique. We generated transgenic parasites that express 
the full-length Lipl2 protein integrated at a non-essential locus in blood stage parasites using 
the Bxb1 integrase system for site specific recombination in parasites6. Using this method to 
over express Lipl2 we observed consistent co-localization of Lipl2 with the mitochondrion 




Lipl2 Expression and Localization 
Lipl2-GFP expression and localization 
 We generated a parasite line that expresses the Lipl2 protein fused to a C-terminal 
Green Fluorescent Protein (Lipl2-GFP) tag. Lipl2-GFP is expressed from the moderate 
strength P. falciparum ribosomal L2 promoter in this experiment. We stained cells with the 
Mitotracker Red (Invitrogen) dye, which stains the mitochondria of the parasite, and 
observed colocalization between Lipl2-GFP and the Mitotracker Red dye (Figure A-1 A). 
This suggests that Lipl2 traffics to the mitochondria in blood stage parasites. In all of the live 
fluorescence cell images that we collected, Lipl2 appears to be co-localized with the 
mitochondria. Figure A-1 A shows a representative image at each stage of parasite 
development in the red blood cell (ring, trophozoite, and schizont). Lipl2 colocalizes with 
the mitochondria at all three stages.   
To further interrogate whether Lipl2 also traffics to the apicoplast we stained fixed 
cells in immunofluorescence assays with antibodies to track the location of Lipl2-GFP and 
the apicoplast marker Acyl-Carrier Protein (ACP). We did not observe significant 
colocalization between Lipl2 and ACP in any of the images we collected (Figure A-1B).  
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Finally we confirmed expression of Lipl2-GFP by western blot. Lipl2-GFP is about 
74kD and we observed a band at the correct size in our analysis of Lipl2-GFP parasite 
lysates (Figure A-1 C). We also observed a smaller band around 50kD. Further experiments 
should be done to determine whether the band at 50kD is an artifact of the cell lysis 
protocol or if it is a cleaved version of the protein that is present in the cell. 
 
Lipl2-mCherry expression and localization 
 We generated a second parasite line that expresses Lipl2 fused to a C-terminal 
mCherry (Lipl2-mCherry) fluorophore. Lipl2-mCherry is expressed from the high strength 
P. falciparum Calmodulin promoter in this parasite line. We stained cells with a Mitotracker 
Green (Invitrogen) dye that stains the mitochondrion of the parasite and again observed 
colocalization between Lipl2 and the Mitotracker dye (Figure A-2). This supports our initial 
observation that Lipl2 traffics to the mitochondria in blood stage parasites. In all of the live 
cell images that we collected, with the Lipl2-mCherry line, Lipl2 appears to be co-localized 
with the mitochondria. 
 
Dual expression of Lipl2-GFP and an apicoplast marker 
 In our final attempt to interrogate whether Lipl2 traffics to the apicoplast we 
designed a plasmid to express Lipl2-GFP and a fluorescent apicoplast marker in parasites. 
We reasoned that this parasite line would allow us to detect Lipl2-GFP colocalized with the 
apicoplast in live fluorescence images.  
The apicoplast marker protein in this experiment is the targeting motif from ACP 
fused to mCherry. We expressed this apicoplast marker from the same promoter as the 
resistance cassette by appending a skip peptide sequence followed by the apicoplast marker 
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sequence to the end of the open reading frame for the resistance cassette (See plasmid map 
in Figure A-3 A). Skip peptides are short amino acid sequences that RNA viruses use to 
express multiple genes from one open reading frame7. When translated, the skip peptide 
sequence impairs formation of a specific peptide bond in its own sequence without affecting 
translation of the next residue. This allows the ribosome to “skip” formation of one peptide 
bond after the first protein in the open reading frame and continue translating the second 
protein7.  
We transfected parasites with the plasmid in Figure A-3 A and analyzed cells for 
expression of Lipl2-GFP and the apicoplast marker. We did not detect expression of Lipl2-
GFP in this parasite line, which suggests that the parasites have turned off expression of the 
transgene while maintaining the resistance cassette. We did detect the cleaved apicoplast 
marker protein in the western blot shown in Figure A-3 B. This blot shows that the skip 
peptide is able to facilitate cleavage of the apicoplast marker protein from Blasticidin S 
Deaminase (BSD), which mediates resistance to blasticidin in parasites. If the skip peptide 
had not worked, we would expect to see a larger band at 49kD on the western blot because 
the BSD protein would still be attached to the apicoplast marker. Although this parasite line 
could not be used to localize Lipl2, it does confirm that the skip peptide is functional in P. 
falciparum.   
 
DISCUSSION AND FUTURE DIRECTIONS 
 
 In this study we over-expressed Lipl2 in parasites in two independent experiments 
using the Bxb1 integrase system to generate transgenic parasites that have integrated Lipl2 at 
a specific locus in the nuclear genome. Studies from another group reported that Lipl2 is 
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dually localized to the apicoplast and the mitochondrion but we did not observe apicoplast 
localization in either of our overexpression lines. In our hands, Lipl2 appears to be 
exclusively localized to the mitochondrion. This result is consistent with our previously 
described functional studies of Lipl2, which showed that Lipl2 has transferase activity and 
works in conjunction with Lipl1.   
Differences in localization between our study and the published report may be due 
to the different methods of overexpression that were utilized in these studies. The previous 
study expressed Lipl2 episomally, which is not ideal for protein over expression in P. 
falciparum because the parasite does not efficiently maintain episomes. Parasites that maintain 
episomes often do not effectively pass the plasmid from one generation to the next and so 
growth of cultures expressing episomal plasmids is significantly slower that normal. Parasites 
can also maintain more than one plasmid and so expression levels may vary between cells8–10.   
Another option to localize the Lipl2 protein is to tag it at its endogenous locus. We 
cannot rule out the possibility that correct timing of expression or protein levels in the cell 
affect trafficking of Lipl2. Tagging Lipl2 at its endogenous locus and analyzing localization 
could provide more insight into the true localization of Lipl2.    
 
METHODS 
Generation of plasmid constructs 
 The Lipl2 gene was PCR amplified from plasmid DNA and then digested with AvrII 
and BsiWI. Vector DNA pLN-mCherry or pRL2-GFP were then also digested with AvrII 
and BsiWI restriction enzymes. Inserts were ligated into the appropriate vector to generate 
plasmids described in this appendix using Quick Ligase (New England BioLabs). DNA 
sequences were confirmed by sequencing after insertion. 
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 The P2A skip peptide and TA-mCherry genes were added to the C-terminus of the 
Blasticidin S Deaminase coding region on the pRL2-Lipl2-GFP plasmid. The TA-mCherry 
gene with an N-terminal P2A sequence fragment was PCR amplified from plasmid DNA 
using TAmCh.P2A.F and TAmCh.Bsu36I.R. The C-terminus of Blasticidin S Deaminase 
was then PCR amplified from plasmid DNA with an overlapping C-terminal P2A fragment 
using BSD.EagI.P2A and BSD.P2A.R. The P2A-TAmCherry and BSD-P2A fragments with 
overlapping P2A sequences were then put into a final PCR reaction with primers to amplify 
the entire BSD-P2A-TAmCherry insert form the ends (BSD.Syn.F and TAmCherry.Syn.R). 
The final PCR product was digested with EagI and Bsu36I and inserted into the pRL2-
Lipl2-GFP vector (also digested with EagI and Bsu36I).  The final DNA sequence was 
confirmed by sequencing after insertion.  
Western blots 
 5mL parasite cultures at 2 % hematocrit were lysed in 0.2 % saponin and washed in 
PBS. Cell pellets were then re-suspended in 5x SDS running buffer. Samples were run on a 
NuPage 4– 12 % Bis-Tris reducing gel (Invitrogen) and then transferred to nitrocellulose. 
The nitrocellulose membrane was then blocked in 5 % milk for 1hour before probing with a 
primary antibody overnight at 4 °C. Nitrocellulose membranes were probed with Living 
Colors mouse anti-GFP JL-8 (Clonetech) used at 1:5000 or rabbit anti-dsRed used at 1:5000. 
The membranes were then washed and probed with appropriate secondary (anti-rabbit 
Horse Radish Peroxidase (HRP) or anti-mouse HRP at 1:5000) antibodies for 1 hour. The 
membranes were then washed again and treated with Super Signal West Pico PLUS (Thermo 
Scientific) reagent before exposure to film.  
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 Live cell imaging and immunofluorescence assays were done using the same methods 
described in chapter 2 
 Parasite transfections methods are the same as in Chapter 2. 
 Parasite culture methods are the same as for Chapter 2 except that these parasites 
were grown in human serum instead of albumax.  
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Figure A-1 Lipl2-GFP Localization 
A) Live fluorescence images of a transgenic parasite line expressing Lipl2 fused to GFP. The 
mitochondrion is stained with Mitotracker Red (Invitrogen). 
B) Immunofluorescence images of the same parasite line in part A. 
C) Western blot analysis of parasites expressing Lipl2 fused to GFP. Parasite lysates have 
been probed with an anti-GFP primary antibody. 
Images are 10μm long by 10μm wide. 




Figure A-2 Lipl2-mCherry Localization 
Live fluorescence images of a transgenic parasite line expressing Lipl2 fused to mCherry. 
The mitochondrion is stained with Mitotracker Green (Invitrogen). 
Images are 10μm long by 10μm wide. 
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Figure A-3 Dual expression of Lipl2-GFP and an apicoplast marker  
A) Map of the parasite expression vector we used to attempt to generate a parasite line that 
expresses Lipl2-GFP and a fluorescent apicoplast marker (mCherry).  
B) Western blot analysis of parasites selected after transfection with the plasmid in part A. 
Parasite lysate was probed with an anti-dsRed primary antibody. 
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Table A-1 Primers used to add an apicoplast marker to the pRL2-Lipl2-GFP plasmid   
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